Transcription Factor EB Activation Rescues Advanced αB-Crystallin Mutation-Induced Cardiomyopathy by Normalizing Desmin Localization

Xiucui Ma, PhD; Kartik Mani, MBBS; Haiyan Liu, MD; Attila Kovacs, MD; John T. Murphy, PhD; Layla Foroughi, BA; Brent A. French, PhD; Carla J. Weinheimer, MS; Aldi Kraja, DSc, PhD; Ivor J. Benjamin, MD, PhD; Joseph A. Hill, MD, PhD; Ali Javaheri, MD, PhD; Abhinav Diwan, MD

Background—Mutations in αB-crystallin result in proteotoxic cardiomyopathy with desmin mislocalization to protein aggregates. Intermittent fasting (IF) is a novel approach to activate transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway, in the myocardium. We tested whether TFEB activation can be harnessed to treat advanced proteotoxic cardiomyopathy.

Methods and Results—Mice overexpressing the R120G mutant of αB-crystallin in cardiomyocytes (Myh6-CryABR120G) were subjected to IF or ad-lib feeding, or transduced with adeno-associated virus–TFEB or adeno-associated virus–green fluorescent protein after development of advanced proteotoxic cardiomyopathy. Adeno-associated virus–short hairpin RNA–mediated knockdown of TFEB and HSPB8 was performed simultaneously with IF. Myh6-CryABR120G mice demonstrated impaired autophagic flux, reduced lysosome abundance, and mammalian target of rapamycin activation in the myocardium. IF resulted in mammalian target of rapamycin inhibition and nuclear translocation of TFEB with restored lysosome abundance and autophagic flux; and reduced aggregates with normalized desmin localization. IF also attenuated left ventricular dilation and myocardial hypertrophy, increased percentage fractional shortening, and increased survival. Adeno-associated virus–TFEB transduction was sufficient to rescue cardiomyopathic manifestations, and resulted in reduced aggregates and normalized desmin localization in Myh6-CryABR120G mice. CryABR120G-expressing hearts demonstrated increased interaction of desmin with αB-crystallin and reduced interaction with chaperone protein, HSPB8, compared with wild type, which was reversed by both IF and TFEB transduction. TFEB stimulated autophagic flux to remove protein aggregates and transcriptionally upregulated HSPB8, to restore normal desmin localization in CryABR120G-expressing cardiomyocytes. Short hairpin RNA–mediated knockdown of TFEB and HSPB8 abrogated IF effects, in vivo.

Conclusions—IF and TFEB activation are clinically relevant therapeutic strategies to rescue advanced R120G αB-crystallin mutant-induced cardiomyopathy by normalizing desmin localization via autophagy-dependent and autophagy-independent mechanisms. (J Am Heart Assoc. 2019;8:e010866. DOI: 10.1161/JAHA.118.010866.)

Key Words: cardiomyopathy • HspB8 • intermittent fasting • protein aggregates • TFEB • αB-crystallin

Mutations in sarcomeric and cardiac cytoskeletal proteins are being increasingly ascribed causative roles in engendering cardiomyopathy spanning the spectrum of dilated, hypertrophic, restrictive, and arrhythmgogenic right ventricular dysplasia phenotypes. One such genetically heterogeneous group of disorders, termed “desminopathies,”...
is characterized by a deficiency or mislocalization of desmin, a muscle-specific type III intermediate filament that serves a critical scaffolding role in linking the sarcomere to other intracellular structures. A cardiac-enriched small heat shock family protein, αB-crystallin, binds desmin; and a missense mutation that leads to an arginine-to-glycine change at position 120 (R120G) results in loss of its chaperone function, with formation of protein aggregates that manifest as an autosomal dominant cardiomyopathy, cataracts, and skeletal myopathy in humans. Analogously, mutations in desmin also provoke cardiomyopathy, and formation of amyloid protein aggregates in cardiac myocytes is a hallmark of disease pathogenesis. Whether facilitating removal of protein aggregates can reverse established cardiomyopathy in patients presenting with a full-blown disease process has not been experimentally evaluated.

Protein aggregation leading to myofibrillar degeneration and sarcomere dysfunction, as well as cardiac myocyte apoptosis and interstitial fibrosis, have been implicated as proximate mechanisms for development of the progressive cardiomyopathy in mice with cardiomyocyte-specific expression of the R120G αB-crystallin mutant (CryABR120G) protein. Although cardiomyocyte protein quality-control pathways (namely, the heat shock family of chaperones, the ubiquitin-proteasome pathway, and autophagy) are induced in these models, further upregulation of small heat shock proteins, overexpression of an 11S subunit to activate proteasomes, and stimulation of autophagy with ATG7 overexpression or exercise are individually sufficient to prevent development of aggregates and attenuate cardiomyopathy. Whether targeting these pathways individually or combinatorially rescues advanced cardiomyopathy with CryABR120G expression has not been evaluated.

Mislocalization of desmin from its physiologic location in association with Z-discs between sarcomeres and intercalated discs at intercellular junctions to protein aggregates is a common feature of CryABR120G-induced cardiomyopathy and desmin-related cardiomyopathies in the human myocardium and in animal models. CryABR120G-expressing mice as well as mice with desmin mutations resulting in loss of its sarcomeric localization demonstrate impaired cardiac myocyte contractility and mitochondrial abnormalities; and desmin null mice demonstrate myofibrillar breakdown with accelerated cardiomyocyte death and cardiomyopathy, pointing to a critical role for desmin in cardiomyocyte homeostasis. The CryABR120G mutant protein binds desmin with increased affinity compared with wild-type αB-crystallin protein, is defective in chaperone function, and gets ubiquitinated to be sequestered in aggregates or targeted for proteolytic degradation. Formation of protein aggregates is protective because strategies to reduce ubiquitination of CryABR120G by targeting the COP9 (Constitutive photomorphogenesis 9) signalosome or preventing its aggregation by depletion of p62 or an adaptor protein that sequesters ubiquitinated proteins in aggregates, enhance CryABR120G-induced cytotoxicity. However, despite accelerating protein aggregate pathologic features with age, cardiac function progressively declines in CryABR120G-expressing hearts, suggesting the hypothesis that sequestration of other proteins, such as desmin, within aggregates may play a pathologic role in the progressive cardiomyopathy. Whether strategies to correct desmin localization will be synergistic with those targeting removal of protein aggregates remains to be explored.

Cardiomyocyte autophagy plays a critical role in slowing progression of CryABR120G-induced cardiomyopathy because concomitant haploinsufficiency of Beclin-1 resulted in accelerated disease progression in a mouse model of human CryABR120G protein expression. In studies presented herein, we have uncovered impairment in autophagic flux at an advanced, preterminal stage of cardiomyopathy, associated with inactivation of transcription factor EB (TFEB), the master regulator of autophagy and lysosomal machinery. Concurrently, we found hyperactivation of mammalian target of rapamycin (mTOR), the kinase that phosphorylates and
inactivates TFEB, thus keeping it sequestered and inactive in the cytosol.25 We have observed that fasting is a potent stimulus for TFEB activation in the myocardium and that intermittent fasting (IF) facilitates mitochondrial quality control and preconditions the myocardium to ischemia-reperfusion injury.26 Herein, we have evaluated the feasibility of IF and TFEB gene therapy, as a strategy to rescue advanced cardiomyopathy resulting from expression of the R120G αB-crystallin mutant protein. Our findings reveal that TFEB activation coordinately drives protein quality control pathways in the myocardium to restore normal desmin localization via accelerating autophagic removal of protein aggregates and transcriptional induction of HSPB8 (Heat Shock Protein Family B (Small) Member 8), to attenuate established cardiomyopathy.

Methods

The authors declare that all supporting data are available within the article. The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedures reported in this article.

Studies in Mice

Transgenic mice with cardiomyocyte-specific expression of R120G mutant of human αB-crystallin protein (i.e., Myh6-CryABR120G transgenic mice described previously)8 and age- and sex-matched littermate controls were used for all the studies. CryAB null mice27 were generously provided by Dr Eric Wawrousek. Echocardiographic studies and IF were performed as previously described (also see Data S1 for details).26 Terminal studies on mice were initiated between 8 and 10 AM after an overnight period of feeding (ie, on a fed day). All animal studies were approved by the Institutional Animal Care and Use Committees at Washington University School of Medicine and at the John Cochran VA Medical Center. Assessment of autophagic flux, in vivo, was performed with injection of chloroquine (40 mg/kg IP, Sigma catalog No. C6628) 4 hours before euthanasia, as previously described.26

Ultrastructural Examination

Transmission electron microscopy was performed on mice hearts fixed in a modified Karnovsky’s fixative, followed by imaging with a JEOL model 1200 EX electron microscope (JEOL, Tokyo, Japan), as previously described.26

Quantitative Polymerase Chain Reaction Analysis

Total RNA was extracted from mouse hearts or neonatal rat cardiac myocytes (NRCMs) using RNAeasy Fibrous Tissue Kit (Qiagen, 74704) or the Mini kit (Qiagen, 74104), respectively. Quantitative polymerase chain reaction analysis was performed as described.26 Primers used are shown in Table S1.

Assessment of Mitochondrial DNA Content

DNA was extracted from NRCMs modeled with adenoviral gain-of function and loss-of-function approach pellets, and real-time quantitative polymerase chain reaction was performed for the mitochondrial gene NADH2 (with primers 5′-ATCACCACTTCTCGCAAT-3′ and 5′-TCTATGTGGGCAA TTGATG-3′) and the nuclear gene RCAN1 (with primers 5′-GG TTTGCTGAGCCTCGAAG-3′ and 5′-CTCTATCCCCTTTGTAAC-3′). The ratio of copies of mitochondrial/nuclear genes was calculated to represent the relative mitochondrial DNA content, as we have previously described.28

Generation of Adenoviral Constructs

Adenoviral particles coding for LacZ and human TFEB with N-terminal FLAG have been described previously.29 Adenoviral particles for expression of short hairpin RNA (shRNA) targeting hspb8 and a LacZ shRNA control were generated with BLOCKiT adenoviral system (Invitrogen, K4941–00). Specific oligonucleotide sequences used were as follows: shRNA targeting rat hspb8−top strand oligonucleotide, 5′-CA CCGTCAAAGATTTGGAAGGTTCGAAAACCTCCCAATACTTTGAC-3′; bottom strand oligonucleotide, 5′-AAAGATCAAGATTTGGG AGGTTCGCAAACCTCCCAATACTTTGAC-3′. Adenoviruses were generated in HEK293A cells and titered per the manufacturer’s instructions.

Generation of Adeno-Associated Virus Constructs

Mouse TFEB cDNA was cloned into a phosphorylated adenoviral vector containing the CMV (cytomegalovirus) promoter (phosphorylated AAV9–CMV–FLAG–TFEB), as we have previously described.30 Coding sequences for human CRYAB and CRYAB protein with the R120G mutation were similarly cloned into a phosphorylated AAV9 vector containing the cardiac-specific troponin T promoter.31 Constructs for in vivo knockdown of mouse endogenous TFEB and HSPB8 were generated using the specific oligonucleotide sequences targeting murine TFEB (5′-CCGGCAGTACTATGAC TATGAT-3′) and HSPB8 (5′-GCCTTTGAAAAGTGTGGTGCCA-3′); and compared with a scrambled control sequence (with no complementarity to murine genome) (5′-CCTAACGTTAAGT GCCCCTG-3′) by cloning into an AAV9 vector under the control of a U6 promoter. AAV9 particles were generated at the Hope Center Viral Vectors Core at Washington University School of Medicine. A 1-time dose of 3.5 × 1011 particles was administered to the mice by tail vein injection.
Subcellular Fractionation Into Cytoplasmic and Nuclear Fractions

Hearts were fractionated into nucleus-enriched and cytoplasmic samples by using a CelLytic NuCLEAR extraction kit (Sigma), as previously described. Isolation of Soluble and Insoluble Fractions

Heart tissue was fractionated into soluble and insoluble fractions, as previously described (also see Data S1 for details).

Immunoblotting

Crude cardiac or NRCM extracts were prepared, followed by immunoblotting, as described. Antibodies used were as follows: LAMP2 (Lysosomal Associated Membrane Protein 2), mouse monoclonal (Developmental Studies Hybridoma Bank, ABL-93); LAMP1 (Santa Cruz Biotechnology, sc-19992); anti-LC3 (encoding for MAP1LC3B (Microtubule Associated Protein 1 Light Chain 3 Beta) subunit; Novus Biologicals, NB100–2220); SQSTM1 (Sequestosome 1) (Abcam, ab5416); TFEB (Bethyl Labs, A303–673A); HA (H6908; Sigma), p70S6K (phosphorylated Ribosomal protein S6 kinase beta-1) (2708; Cell Signaling); phosphorylated p70S6K (9234; Cell Signaling); 4-EBP1 (Eukaryotic translation initiation factor 4E-binding protein 1) (9644; Cell Signaling); phosphorylated 4EBP1 (2855; Cell Signaling); phosphorylated mTOR (2974; Cell Signaling); phosphorylated mTOR (2983; Cell Signaling); histone H3 (9715, Cell Signaling); GAPDH (ab22555; Abcam); Hspb8 (3059S, Cell signaling); and ACTA1/α-sarcomeric actin (Abcam, ab7799) or actin (Sigma, A2066). Protein abundance was normalized to actin or GAPDH protein expression and reported as fold change versus control.

Immunofluorescence Analysis

Primary cultures of NRCMs were fixed in 100% cold methanol for 20 minutes, followed by blocking with 1% normal serum in PBS for 1 hour at room temperature. Primary antibodies used were as follows: anti-desmin (Santa Cruz Biotechnology, Inc, SC-7559), anti–αB-crystallin polyclonal antibody (ENZO Life, ADI-SPA-223-F), anti-p62/SQSTM1 (PROGEN Biotechnik, GP62-C), anti–ubiquitinated FK-2 (Millipore; 04-263), and TFEB (Bethyl Labs, A303–673A) with overnight incubation at 4°C. Paraffin-embedded heart sections (10 μm thick) were subjected to heat-induced epitope retrieval, followed by blocking, and incubated overnight with primary antibody against desmin (Santa Cruz Biotechnology, SC-7559). After serial washes, samples were stained with AlexaFluor488 (Invitrogen) and mounted with fluorescent 4′,6-diamidino-2-phenylindole mounting medium (Vector Labs, H-1200). Confocal imaging was performed on a Zeiss confocal LSM-700 laser scanning confocal microscope using 63× Zeiss Plan-Neofluar 40×/1.3 and 63×/1.4 oil immersion objectives, and images were acquired using Zen 2010 software. Assessment of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling positivity in myocardial samples was performed as previously described. Intracellular protein aggregates in cardiac myocytes were quantitated on ×20 images of paraffin-fixed tissue immunostained for desmin. Aggregates were identified using the ImageJ software by counting particles greater than a predefined threshold size and assessing an automated aggregate area as a percentage of the total area. A minimum of 10 images per heart were counted to obtain the average aggregate area percentage. At least 3 biological replicates were assessed for each group.

Flow Cytometry

NRCMs were incubated with JC-1 (10 mg/mL for 10 minutes) at 37°C in 5% CO₂, followed by trypsinization and flow cytometry on a FACScan instrument (Becton-Dickinson), as previously described. CytoFlor software was used to analyze 20 000 events per run.

Assessment of Cell Death

Cell death assays were performed in 96-well plates with a Live-Dead cytotoxicity viability kit for mammalian cells (Invitrogen), as described previously.

Coimmunoprecipitation Assays

One milligram of protein from the mouse hearts was incubated with anti-desmin (SC7559; Santa Cruz Biotechno-
yogy), anti-mouse FLAG (F3165; Sigma), and normal goat IgG (SC2028, Santa Cruz Biotechnology) or normal mouse IgG (SC2025, Santa Cruz Biotechnology); immunoprecipitation was performed using Dynabeads Protein G Immunoprecipitation Kit (Thermo Fisher Scientific, 10007D). The eluted samples are analyzed by SDS-PAGE, followed by Western blot, to detect desmin (anti-desmin, D1033, Sigma), αB-crystallin (anti–αB-crystallin, ADI-SPA-223-F, Enzo Life), and HSPB8/HSP22 (anti-HSPB8/HSP22, 3059S, Cell Signaling).

Statistical Analysis

Results are expressed as mean±SEM. Statistical differences were assessed with the unpaired Student t test for 2 independent groups and ANOVA for comparing results across multiple groups with GraphPad Prism software. Tukey’s post hoc test was used after ANOVA for testing all pair-wise comparisons. To overcome the limitations with large-sample approximations using the above approaches, we redid the analysis using 2 additional statistical software programs for comparing results: R and SAS. With R, we performed t tests with permutation correction for P values by using permTS function of library “perm” of R, selecting method=“exact.ce” in
permTS for a complete enumeration. We also tested such analyses via MULTTEST of SAS with mean t test for continuous variables by selecting “pooled” degrees of freedom, “2-tailed” tails for continuous tests, and “permutation” P-value adjustment by selecting “20 000” number of resamples and a random seed. Application of the permTS (R) and MULTTEST (SAS) produced identical results. We have reported the R permTS function P value in Data S1 for quantitative analyses presented in Figures 1 through 8. Log-rank statistic was used to assess differences in survival. A 2-tailed value of $P<0.05$ was considered statistically significant.

Results

Autophagic Flux Is Impaired in CryABR120G Transgenic Mice With Advanced Cardiomyopathy

To address the role of autophagy in treatment of established CryABR120G-induced cardiomyopathy, as typically observed in individuals harboring this mutation when they first seek clinical attention, we examined autophagic flux in 40-week-old transgenic mice expressing the human R120G αB-crystallin mutant protein in cardiac myocytes (Myh6-CryABR120G). A sudden and marked increase in mortality is observed at this time in this model, accompanying widespread protein aggregate pathologic features in cardiomyocytes and an end-stage cardiomyopathy phenotype. As shown in Figure 1A through 1C, short-term inhibition of lysosomal acidification with chloroquine resulted in accumulation of LC3-II (the autophagosome bound form of LC3, an index of autophagosome abundance) and p62 (SQSTM1, an adaptor protein that becomes degraded via autophagy) in wild-type hearts compared with diluent-treated counterparts. Myh6-CryABR120G transgenic hearts demonstrated a marked increase in both LC3-II and p62 compared with wild type, which did not change further with chloroquine treatment (Figure 1A through 1C). To confirm that chloroquine treatment was effective in impairing autophagosome processing in the Myh6-CryABR120G

Figure 1. Autophagic flux is impaired in αB-crystallin R120G mutant transgenic mice with onset of heart failure. A through D, Representative immunoblots (A) demonstrating expression of LC3 with quantitation of LC3-II (B), p62 (C) and αB-crystallin (D) in Myh6-CryABR120G transgenic mice or littermate wild-type (WT) controls at 40 weeks of age, injected with chloroquine (40 mg/kg) or diluent to assess autophagic flux. N=4 to 6/group. E, Representative myocardial transmission electron micrographs from in Myh6-CryABR120G transgenic mice or littermate WT controls at 40 weeks of age. Arrows point to Z-discs, and arrowheads point to autophagic structures. Representative of N=2/group. *$P<0.05$. DOI: 10.1161/JAHA.118.010866
TFEB Rescues Proteotoxic Cardiomyopathy
Ma et al

Failure, autophagic flux was preserved (Figure S1B and S1C). Taken together, these data indicate impaired flux through macroautophagy (henceforth termed “autophagy”) in Myh6-CryABR120G transgenics with advanced cardiomyopathy compared with the preserved flux seen in wild-type controls. Interestingly, α-B-crystallin levels are also upregulated in chloroquine- versus diluent-treated wild-type hearts (Figure 1A and 1D), indicating the normal turnover of this chaperone is, at least in part, via autophagy in mice at this age. Interestingly, cardiac extracts from Myh6-CryABR120G transgenic mice demonstrated both slower and faster migrating bands on PAGE gels, which were confirmed to be α-B-crystallin protein (Figure S2) and likely represent ubiquitinated aggregates and cleavage products of the mutant crystallin protein, respectively, as previously described.22 The abundance of α-B-crystallin protein did not change with chloroquine treatment in the Myh6-CryABR120G transgenic mice, consistent with impaired autophagic flux (Figure 1A and 1D). Ultrastructural examination of the cardiomyopathic Myh6-CryABR120G myocardium in aged mice revealed accumulation of multiple autophagic structures (arrowheads, Figure 1E) as well as effaced Z-discs (arrows, Figure 1E; with broad and often zig-zag patterned Z-discs in transgenics, as previously observed in a transgenic model with overexpression of mouse CryABR120G protein6 versus sharp Z-discs in controls), consistent with the altered localization of desmin adjacent to the Z-disc in this condition.

IF Restores Autophagic Flux and Rescues Lethality in CryABR120G Transgenic Mice With Advanced Cardiomyopathy

We have observed that IF transcriptionally upregulates the autophagy-lysosome machinery and stimulates autophagic flux to precondition the heart to ischemia-reperfusion injury and reduce cardiomyocyte cell death.26 More important, in this study, IF did not affect cardiac structure or function in wild-type mice.26 Accordingly, we tested if IF could rescue the impaired autophagic flux in the immediate preterminal stage in Myh6-CryABR120G transgenic mice with advanced cardiomyopathy (Figure 2A). Remarkably, IF over a period of 6 weeks completely prevented the mortality observed in Myh6-CryABR120G mice over this period (Figure 2B). Examination of the state of activation of TFEB, the master regulator of the autophagy-lysosome machinery, revealed that in comparison to age-matched wild-type controls, the abundance of nuclear TFEB (where it localizes to upon activation)25 was similar and cytosolic TFEB levels were reduced (Figure 2C and 2D). Because TFEB transcriptionally autoregulates its own expression,32 these data point to a failure of the transcriptional response that drives the autophagy-lysosome pathway despite active protein aggregate pathologic features, consistent with the previous observation of reduced autophagy-lysosome pathway gene transcripts in mice with transgenic expression of the murine CryABR120G mutant.15,33,34 Interestingly, IF significantly increased nuclear TFEB abundance in Myh6-CryABR120G mice compared with their ad-lib fed counterparts (Figure 2C and 2D), and this was associated with rescue of autophagic flux impairment, as indicated with chloroquine-induced upregulation of LC3-II and p62 levels versus respective diluent-treated group (Figure 2E and 2F). The lack of TFEB activation was accompanied by reduction in LAMP1 and LAMP2 levels in ad-lib fed Myh6-CryABR120G mice (versus wild-type mice, Figure 2G and 2H), suggestive of a reduction in lysosome abundance, which was restored to wild-type levels with IF. To examine the mechanism for the lack of TFEB activation despite the advanced protein-aggregate pathologic features in the Myh6-CryABR120G myocardium, we assayed mTOR activity, which phosphorylates TFEB to prevent its nuclear translocation.25 Aged Myh6-CryABR120G mouse hearts demonstrated increased levels of phosphorylated mTOR and its substrates, p70S6 kinase and 4EBP1, compared with wild-type hearts, indicating increased mTOR activity, as observed previously in mice with transgenic expression of the murine CryABR120G mutant,34 which was attenuated with IF (Figure 2I and 2J).

IF Accelerates Protein Aggregate Removal in CryABR120G Transgenic Hearts

Prior studies have demonstrated that activation of autophagy is both necessary and sufficient to prevent formation of protein aggregates in cardiac myocytes expressing the CryABR120G protein.7,33 To determine if restoration of autophagic flux was sufficient to remove protein aggregates, we examined α-B-crystallin protein expression in Myh6-CryABR120G transgenic hearts fractionated into soluble and insoluble fractions.7 As shown in Figure 3A through 3C, intermittently fasted mice demonstrated reduced levels of soluble α-B-crystallin protein, as well as insoluble α-B-crystallin either in monomeric or aggregate form, compared with ad-lib fed counterparts. Examination of myocardial ultrastructure demonstrated qualitatively fewer protein aggregates (Figure 3D, white arrows), with more abundant autolysosomes (black arrows), and reappearance of sharp Z-discs, as seen in wild-type controls, indicating partial restoration of Z-disc ultrastructure in Myh6-CryABR120G transgenic hearts with advanced cardiomyopathy (black arrowheads, compare with broad Z-discs in ad-lib fed Myh6-CryABR120G myocardium).
IF Attenuates Cardiomyopathy and Restores Desmin Localization in CryABR120G Transgenic Mice

Echocardiographic characterization of intermittently fasted and ad-lib fed Myh6-CryABR120G mice revealed attenuation of left ventricular (LV) dilation (Figure 4A and 4B, Table S2), improved ejection performance (percentage LV endocardial fractional shortening, Figure 4A and 4C, Table S2), and attenuated hypertrophy (with reduced LV mass [Figure 4A and 4D] and heart weight [Figure 4A and 4E]) with IF, indicating that restoration of autophagic flux with IF correlated with

Figure 2. Intermittent fasting (IF) activates transcription factor EB (TFEB) and restores autophagic flux in \( \alpha \)-crystallin R120G mutant transgenic mice. A, Schematic depicting experimental intervention with IF in Myh6-CryABR120G transgenic mice. B, Survival curves in IF and ad-lib (AL) fed Myh6-CryABR120G transgenic mice and AL fed controls over the 6-week experimental duration. P value depicted is by log-rank test. C and D, Representative immunoblots (C) demonstrating expression of TFEB with quantitation (D) in the cytosolic and nuclear fractions from hearts of mice treated as in A (at 46 weeks) and subjected to biochemical fractionation. Expression of GAPDH and histone H3 is used to detect enrichment of cytosolic and nuclear proteins, respectively. N=4/group. E, Assessment of autophagic flux in mice Myh6-CryABR120G transgenic mice subjected to IF or provided access to food AL as in A, and injected with chloroquine (40 mg/kg for 4 hours) or diluent with immunoblotting for LC3 and p62. F, Quantitation of LC3-II and p62 in cardiac tissue from mice treated as in E. N=4/group. G and H, Representative immunoblot (G) with quantitation (H) of lysosome proteins LAMP1 and LAMP2 in total cardiac protein extracts from Myh6-CryABR120G transgenic mice subjected to IF or AL feeding, or littermate wild type (WT) as in A. N=4/group. I and J, Representative immunoblots (I) demonstrating expression of mammalian target of rapamycin (mTOR) pathway proteins with quantitation (J) of phosphorylated mTOR (p-mTOR), phosphorylated 70S6K (p-S6K), and phosphorylated 4EBP1 (p-4EBP1) in Myh6-\( \alpha \)-crystallin R120G transgenic mice subjected to IF or AL feeding, and WT controls as in A. N=4/group. qOD (every other day). {*} P value by post hoc test after 1-way ANOVA.

DOI: 10.1161/JAHA.118.010866
attenuation of typical progression of the fatal cardiomyopathic manifestations, otherwise observed with expression of CryABR120G protein.6,8 Intermittently fasted Myh6-CryABR120G myocardium demonstrated fewer eosinophilic aggregates (Figure 4F [arrows] and 4H, with quantification in Figure S3A) with reduction in myocardial fibrosis (Figure 4G) and cell death (Figure S3B and S3C) compared with ad-lib counterparts. We also observed that the normal distribution of desmin associated with Z-discs (multiple arrows in groups) and intercalated discs (single arrow) seen in wild-type cardiomyocytes was largely lost in Myh6-CryABR120G transgenic mice and replaced by desmin localized to aggregates (Figure 4H, with appearance of a hollow core on immunohistochemistry secondary to lack of antibody penetration into aggregates, as observed previously6). Intriguingly, IF restored the expression of desmin in association with Z-discs and intercalated discs (Figure 4H; multiple arrows in groups and single arrows, respectively) in the Myh6-CryABR120G myocardium. To determine if this was secondary to synthesis of new desmin, we measured its transcripts. Our data demonstrate that although desmin transcripts are induced in Myh6-CryABR120G hearts (versus wild type, Figure S4A), presumably to compensate for reduced desmin localized to Z-discs and intercalated discs, we did not see further upregulation with IF, which suggests that IF restored localization of preexisting desmin associated with removal of the αB-crystallin aggregates.

AAV9-Mediated TFEB Transduction Rescues Advanced Cardiomyopathy in CryABR120G Transgenic Mice

We next tested if TFEB activation was sufficient to attenuate the cardiomyopathic manifestations in Myh6-CryABR120G mice at an advanced stage of disease. To do so in a clinically relevant manner, we performed AAV9-mediated gene transfer of mouse TFEB via intravenous injection (versus AAV9–green fluorescent protein as control) at 36 weeks of age and...
confirmed cardiac myocyte targeting at 40 weeks of age
(Figure 5A; data not shown and vide infra). AAV9-mediated
TFEB transduction resulted in modest upregulation of myocar-
dial TFEB abundance (4-fold over control, see Figure 5B and
5C [left]) with increased abundance of nuclear TFEB (Fig-
ure S5A) and of TFEB target proteins (Figure S5B through
S5F). This was suf-
fi
cient to result in reduced abundance of
a-B-crystallin, including the higher-molecular-weight forms
versus AAV9
–
green
fluorescent protein transduced myocar-
dium (Figure 5B and 5C [right]) without affecting human
CryABR120G transgene transcript levels (Figure S6A), gener-
alized protein synthesis (Figure S6B and S6C), or mTOR
activity (Figure S6D). More important, a modest upregulation
of myocardial TFEB levels did not adversely affect left
ventricular structure or function or myocardial architecture
and fibrosis compared with AAV9–green fluorescent protein
transduced controls (Figure 5D through 5J). AAV9-mediated
TFEB transduction improved LV ejection performance (LV
percentage fractional shortening; Figure 5D and 5F, Table S3),
significantly reduced LV end-systolic diameter (Table S3),
and attenuated hypertrophy (with reduced LV mass [Figure 5D
and 5G, Table S3] and heart weight [Figure 5D and 5H])
without an effect on LV dilation (Figure 5D and 5E, Table S3)
in Myh6-CryABR120G mice with advanced cardiomyopathy.
This was associated with reduced aggregates in the
myocardium (Figure 5I, Figure S7A), reduced
fibrosis (Fig-
ure 5J), and reduced myocardial cell death (Figure S7B and
S7C), consistent with the notion that exogenous TFEB was
sufficient to remove protein aggregates and attenuate
cardiomyopathic manifestations at an advanced stage of
pathology in mice expressing CryABR120G, mimicking the
benefits observed with IF (Figure 4).

**TFEB Activation Alters Desmin Interaction With a-B-Crystallin and HSPB8 to Restore Desmin Localization in CryABR120G Cardiomyopathic Hearts**

We next examined if TFEB transduction altered desmin localization. AAV9-mediated TFEB transduction did not affect
desmin localization associated with the Z-discs (multiple
arrows in groups, Figure 6A) or the intercalated discs (single
arrow, Figure 6A) in wild-type mice. More important, AAV9-
TFEB transduction restored the normal pattern of desmin
localization associated with the Z-discs and intercalated discs in the Myh6-CryABR120G myocardium, in cardiomyocytes that demonstrate nuclear TFEB expression (Figure 6A). This suggested the hypothesis that TFEB transcriptionally upregulates other members of the heat shock protein family to chaperone desmin to its normal localization. Prior studies have suggested that expression of recombinant HSPB1 (HSP22) and HSPB8 (HSP25), 2 members of the non-ATPase-dependent heat shock protein family that αB-crystallin belongs to, are sufficient to prevent CryABR120G amyloid oligomer formation.12 In addition, induction of HSPB8 either genetically or pharmacologically attenuated the development of cardiomyopathic manifestations in mice expressing CryABR120G in cardiac myocytes.35 We examined the protein levels of these 2 small heat shock family proteins in the TFEB (or green fluorescent protein)–transduced Myh6-CryABR120G transgenic mice and wild-type controls, and found that both are increased in Myh6-CryABR120G transgenic myocardium versus control (Figure 6B through 6D). Interestingly, TFEB transduction resulted in further increase in protein levels of HSPB8 (Figure 6B and 6C), but not HSPB1 (Figure 6B and 6D), in both wild-type and Myh6-CryABR120G transgenic mice, consistent with the previously described presence of TFEB-binding CLEAR (Coordinated Lysosomal Expression and Regulation) sites in the HSPB8 promoter.36 Indeed, exogenous TFEB was sufficient to selectively upregulate HSPB8 transcripts in NRCMs after short-term transduction (Figure S8). Interestingly, myocardial HSPB8 transcript and protein levels were also upregulated with fasting (Figure S9A through S9C) and return to baseline levels with refeeding (Figure S9B and S9C), tracking the pulsed activation of myocardial TFEB with each episode that we have described previously,26 without an increase on a fed day noted at the termination of the 6 weeks of IF (Figure S9D and S9E).

The mechanism for TFEB-induced normalization of desmin localization could be increased degradation of desmin from the protein aggregates and resynthesis of new desmin that gets chaperoned to its right location. We determined this to be less likely because we did not detect a change in total desmin protein abundance (Figure 6B and 6E) or in desmin transcripts in the AAV9-TFEB treated samples (Figure S4B). The alternative explanation is that desmin protein is held in a strong interaction with the mutant αB-crystallin protein,21 which is targeted to the aggregates. Indeed, immunoprecipitation studies with AAV9-based cardiac-myocyte specific expression of R120G mutant of CryAB and wild-type CryAB...
proteins, driven by the cardiac troponin T promoter, demonstrate that desmin interacts more avidly with the mutant protein, in vivo (Figure S10A through S10D). TFEB-mediated autophagic removal of the ubiquitinated mutant αB-crystallin protein then frees up desmin, which binds to HSPB8 and is chaperoned back to its normal location in association with the Z-discs and intercalated discs. Indeed, coimmunoprecipitation experiments demonstrated that desmin interaction with αB-crystallin is markedly upregulated in the Myh6-CryABR120G hearts, whereas its interaction with HSPB8 is concurrently diminished compared with wild type (Figure 6F). Interestingly, both IF and AAV9-TFEB transduction resulted in a downregulation of desmin’s interaction with αB-crystallin with a simultaneous increase in HSPB8 protein that was immunoprecipitated with desmin (Figure 6F and 6G); and IF did not alter ubiquitination of desmin (Figure S11). Taken together, these data suggest that TFEB accelerates clearance of the mutant αB-crystallin protein that sequesters desmin, whereby desmin is freed up to interact with HSPB8 and is, therefore, able to return to its correct location adjacent to the Z-discs and intercalated discs.

TFEB Increases Autophagic Flux to Drive Degradation of Mutant αB-Crystallin Independent of HSPB8 Induction

To examine the effect of targeting TFEB activation and the role of HSPB8 in autophagic removal of protein aggregates, we adenovirally transduced CryABR120G in NRCMs together with exogenous TFEB, with and without concomitant shRNA-mediated HSPB8 knockdown (Figure S12A). TFEB transduction upregulated HSPB8 protein abundance (Figure S12A and S12B) and induced autophagic flux in control-adenovirus transduced myocytes, with accumulation of LC3-II and p62 in cells treated with baflomycin A1 to inhibit lysosomal acidification versus diluent-treated controls (Figure S12A, S12C, and S12D). Expression of R120G αB-crystallin mutant resulted in impaired autophagic flux (lack of baflomycin A1–induced accumulation of LC3-II and p62 [Figure S12A, S12C, and S12D]), whereas concomitant TFEB transduction restored autophagic flux. More important, knockdown of HSPB8 did not prevent TFEB-induced upregulation of autophagic flux (Figure S12A, S12C, and S12D) in cardiomyocytes expressing either CryABR120G or control. TFEB transduction resulted in reduced expression of αB-crystallin...
protein (Figure S12A and S12E), including the high-molecular-weight aggregates specifically from the insoluble fractions (Figure S12A and S13), and knockdown of HSPB8 did not affect this decline (Figure S12E). Taken together, these data indicate that TFEB drives removal of CryABR120G protein aggregates via induction of autophagic flux independent of HSPB8 induction.
TFEB Induces Normalization of Desmin Expression, Preserves Mitochondrial Polarization, and Attenuates Cell Death in Cardiomyocytes via HSPB8 Induction

We next evaluated the effect of TFEB on desmin localization in NRCMs, cultured to induce sarcomere formation, which resulted in desmin localization to the Z-discs (see arrows in groups in top row, in Figure 7A). Adenoviral expression of CryABR120G induced formation of aggregates and relocalization of desmin from the Z-discs to aggregates (see single arrows in second row, Figure 7A). Overexpression of TFEB resulted in marked reduction of protein aggregates and reappearance of desmin at the Z-discs (third row, Figure 7A). Remarkably, concomitant knockdown of HSPB8 completely prevented TFEB-induced relocalization of desmin to the Z-discs, without affecting TFEB-induced reduction of aggregates in cardiomyocytes expressing CryABR120G (bottom row, Figure 7A).

To confirm the presence of protein aggregates and their removal by TFEB expression, we evaluated the localization of p62, an adaptor protein that binds to ubiquitinated proteins to facilitate aggregate formation. Both αβ-crystallin and desmin colocalized with p62 and ubiquitin in puncta in CryABR120G-transduced cardiac myocytes (see single arrows, second row, Figure 7B), and desmin was no longer localized to Z-discs, as observed in controls (arrows in groups, top row, Figure 7B). TFEB transduction in CryABR120G-expressing cardiac myocytes resulted in removal of p62 and ubiquitin-positive aggregates in an HSPB8-independent manner and normalization of desmin localization in an HSPB-dependent manner (compare third and fourth rows, Figure 7B).

Given the recently elucidated role for Z-disc–associated desmin as a scaffold for mitochondria and maintaining their polarization,37 we examined the effect of TFEB in CryABR120G-transduced cells on mitochondrial membrane potential assessed with a ratiometric dye, JC-1. Cells transduced with CryABR120G demonstrated a marked increase in prevalence of depolarized mitochondria (Figure 7C and 7D), as well as increase in mitochondrial DNA content compared with controls (Figure 7E), indicating accumulation of damaged mitochondria in the setting of impaired autophagic flux (Figure S12A, S12C, and S12D). This was accompanied by increased cell death (Figure 7F), as described previously.37 Concomitant TFEB transduction markedly attenuated the CryABR120G-induced increase in mitochondrial depolarization (Figure 7C and 7D) and reduced mitochondrial DNA content (Figure 7E), indicating removal of damaged mitochondria by TFEB-induced restoration of autophagic flux in this setting (Figure S12A, S12C, and S12D). This was accompanied by a reduction in cell death (Figure 7F), in an HSPB8-dependent manner. Intriguingly, shRNA-mediated HSPB8 knockdown was sufficient to modestly increase the prevalence of depolarized mitochondria and cell death, suggesting that it plays a critical role in cardiac myocytes, in vitro, in a resting state. These findings indicate that TFEB activation drives normalization of desmin localization via both autophagy-dependent and autophagy-independent (HSPB8-mediated) mechanisms, thereby preserving mitochondrial quality and cell viability as the likely mechanism in the attenuation of CryABR120G-induced cardiomyopathy.
To determine the mechanistic role of TFEB and HSPB8 in the beneficial response to IF, we transduced 36-week-old mice with AAV9 particles encoding shRNA constructs targeting TFEB and HSPB8 or a nontargeting scrambled control. Baseline echocardiography was performed after 4 weeks, and mice were subjected to IF with repeated echocardiographic evaluation 3 and 6 weeks later, followed by postmortem analysis (Figure S13A). Viral transduction with the shRNA constructs results in ≈65% reduction in TFEB protein expression (with reduced levels of nuclear TFEB, Figure S14) and ≈70% reduction in
HSPB8 protein compared with the control (Figure 8A through 8C). Interestingly, basal HSPB8 levels were also significantly reduced in AAV9–short hairpin TFEB (shTFEB) treated samples (compared with controls), confirming that HSPB8 is a TFEB target, in vivo (Figure 8A and 8C). We did not observe an effect of TFEB and HSPB8 knockdown on cardiac structure and function in the Myh6-CryABR120G mice at 4 weeks after AAV injections to transduce shRNAs targeting TFEB and HSPB8 compared with control shRNA during a period of ad-lib feeding (Figure 8D, Table S4). IF resulted in statistically significant improvement in LV ejection performance (LV percentage fractional shortening, Figure 8D, Table S4) in the Myh6-CryABR120G mice transduced with the control shRNA and abrogation of LV dilation (Figure S14B, Table S4), similar to prior observations with IF in non–AAV9-transduced mice (Figure 4C). By contrast, mice transduced with AAV9-shTFEB as well as with AAV9–short hairpin HSPB8 (shHSPB8) did not demonstrate abrogation of progressive dilation and decline in LV systolic function compared with baseline, despite undergoing IF (Figure 8D, Figure S14B, Table S4). There was no change in body weight within any treatment group over this period (Figure S14C, Table S4). As observed in non–AAV9-treated group (Figure 4F through 4H), IF resulted in reduced eosinophilic aggregates and fibrosis as well as restoration of desmin localization in Myh6-CryABR120G mice treated with AAV9–short hairpin control (Figure 8E through 8G). By contrast, AAV9-shTFEB and AAV9-shHSPB8 transduced Myh6-CryABR120G transgenic mice showed increased aggregate pathologic features and fibrosis as well as persistent abnormal desmin localization away from Z-discs and intercalated discs, and in the aggregates, despite IF (Figure 8E through 8G).

Quantitation of aggregates revealed a significantly increased aggregate load in both shTFEB- and shHSPB8-transduced groups compared with short hairpin control (Figure S15A) and increased abundance of αβ-crystallin, including the higher-molecular-weight forms in shTFEB- and shHSPB8–versus short hairpin control–transduced myocardium (Figure S15B). Interestingly, shHSPB8 transduction appeared to partially affect autophagic flux, which appeared preserved in short hairpin control group and abrogated with shTFEB transduction in intermittently fasted Myh6-CryABR120G transgenic mice (Figure S14D), indicating a role for HSPB8 in facilitating autophagic flux, in vivo, over a prolonged duration of observation. Taken together, these data indicate IF benefits require both TFEB and HSPB8 in the setting of advanced αβ-crystallin R120G mutation-induced cardiomyopathy, consistent with the observation that TFEB activation is sufficient, per se, in transducing these benefits via mechanisms dependent on autophagy and HSPB8 induction.

Discussion

Myofibrillar cardiomyopathies such as observed with autosomal dominant inheritance of the R120G αβ-crystallin mutant protein increase mortality and morbidity attributable to heart failure, necessitating development of therapeutic approaches targeting specific pathobiologic mechanisms. Although prior studies have examined the efficacy of interventions to prevent and/or delay the onset of cardiomyopathy, the current study is the first to demonstrate rescue of advanced cardiomyopathy at a preterminal stage characterized by signs of heart failure. Furthermore, we establish IF and TFEB-gene

DOI: 10.1161/JAHA.118.010866
Figure 7. Transcription factor EB (TFEB) normalizes desmin localization via HSPB8 and promotes aggregate removal independent of HSPB8 expression. A, Representative confocal images demonstrating immunolocalization of desmin and αB-crystallin in neonatal rat cardiac myocytes (NRCMs) adenovirally transduced with TFEB or control, with and without simultaneous knockdown of HSPB8 [ie, treated with adenoviral particles coding for R120G mutant of αB-crystallin [multiplicity of infection {MOI}=10; for 48 hours] without or with HA-tagged TFEB [MOI=10; for 24 hours] in the presence of adenoviral particles expressing short hairpin RNA targeting rat HSPB8 [short hairpin HSPB8 {shHSPB8}; MOI=100; for 72 hours]). Adenoviral particles coding for LacZ or short hairpin LacZ were added as controls simultaneously with Ad-TFEB or Ad-αB-crystallin overexpression and shHSPB8, respectively, to equalize the number of viral particles. Arrows point to desmin in Z-discs, and arrowheads point to desmin colocalized with αB-crystallin in aggregates. Representative of n=2 experiments. B, Representative confocal images demonstrating expression of desmin, ubiquitin, and p62 in NRCMs treated as in A. Arrows point to desmin in Z-discs, and arrowheads point to desmin colocalized with p62 and ubiquitin in aggregates. Representative of n=2 experiments. C and D, Representative flow cytometric tracings demonstrating JC-1 fluorescence (C) and quantitation of cells predominantly expressing JC-1 monomers (fold over control) (D) for NRCMs treated as described for A. N=7/group. E, Mitochondrial DNA content indexed to nuclear DNA in cells treated as in A. N=4/group. F, Cell death in NRCMs treated as in A. N=7 to 8/group. *P<0.05 by post hoc test after 1-way ANOVA.
Knockdown of transcription factor EB (TFEB) and HSPB8 prevents intermittent fasting (IF)–mediated attenuation of proteotoxic cardiomyopathy with persistent desmin localization to aggregates. A through C, Representative immunoblot (A) with quantitation of TFEB expression (B) and HSPB8 abundance (C) in total cardiac protein extracts from Myh6-CryABR120G transgenic mice transduced with adeno-associated virus (AAV9)–short hairpin control (shCon), AAV9–short hairpin TFEB (shTFEB), or AAV9–short hairpin HSPB8 (shHSPB8) and subjected to IF, assessed at 46 weeks of age. N=4/group. *P<0.05 by post hoc test after 1-way ANOVA. Please see schematic in Figure S12A for experimental design. D, Left ventricular percentage endocardial fractional shortening (LV %FS) in mice treated as in A and evaluated by echocardiography at baseline (4 weeks after injection of AAV9 particles and before IF, time=0 weeks) and 3 weeks and 6 weeks after initiating IF. N=4 to 5/group. *P<0.05 by post hoc test after 2-way ANOVA. We did not observe mortality in these treatment groups. See Table S4 for additional echocardiographic data on these mice. E through G, Representative images demonstrating myocardial sections stained with hematoxylin-eosin (H and E; E) and Masson’s trichrome (F) and immunostained for desmin expression (G) in mice treated as in A. In G, white arrows in groups point to Z-discs and arrowheads indicate intercalated discs to demonstrate desmin localization. Single long white arrows point to desmin localized in aggregates. H, Schematic depicting the mechanisms by which IF benefits advanced cardiomyopathy triggered by αB-crystallin R120G mutation. Mutant R120G crystallin expression drives mammalian target of rapamycin (mTOR) activation with suppressed autophagic flux and aggregates sequestering desmin within the aggregates, thereby provoking mitochondrial abnormalities and cell death. IF suppresses mTOR activation, which activates TFEB to stimulate lysosome biogenesis and restores autophagic flux to remove mutant crystallin aggregates and relieve desmin sequestration. TFEB activation also stimulates HSPB8 expression, which chaperones desmin to its normal localization and restores mitochondrial quality to rescue cell death.

Figure 8. Knockdown of transcription factor EB (TFEB) and HSPB8 prevents intermittent fasting (IF)–mediated attenuation of proteotoxic cardiomyopathy with persistent desmin localization to aggregates. A through C, Representative immunoblot (A) with quantitation of TFEB expression (B) and HSPB8 abundance (C) in total cardiac protein extracts from Myh6-CryABR120G transgenic mice transduced with adeno-associated virus (AAV9)–short hairpin control (shCon), AAV9–short hairpin TFEB (shTFEB), or AAV9–short hairpin HSPB8 (shHSPB8) and subjected to IF, assessed at 46 weeks of age. N=4/group. *P<0.05 by post hoc test after 1-way ANOVA. Please see schematic in Figure S12A for experimental design. D, Left ventricular percentage endocardial fractional shortening (LV %FS) in mice treated as in A and evaluated by echocardiography at baseline (4 weeks after injection of AAV9 particles and before IF, time=0 weeks) and 3 weeks and 6 weeks after initiating IF. N=4 to 5/group. *P<0.05 by post hoc test after 2-way ANOVA. We did not observe mortality in these treatment groups. See Table S4 for additional echocardiographic data on these mice. E through G, Representative images demonstrating myocardial sections stained with hematoxylin-eosin (H and E; E) and Masson’s trichrome (F) and immunostained for desmin expression (G) in mice treated as in A. In G, white arrows in groups point to Z-discs and arrowheads indicate intercalated discs to demonstrate desmin localization. Single long white arrows point to desmin localized in aggregates. H, Schematic depicting the mechanisms by which IF benefits advanced cardiomyopathy triggered by αB-crystallin R120G mutation. Mutant R120G crystallin expression drives mammalian target of rapamycin (mTOR) activation with suppressed autophagic flux and aggregates sequestering desmin within the aggregates, thereby provoking mitochondrial abnormalities and cell death. IF suppresses mTOR activation, which activates TFEB to stimulate lysosome biogenesis and restores autophagic flux to remove mutant crystallin aggregates and relieve desmin sequestration. TFEB activation also stimulates HSPB8 expression, which chaperones desmin to its normal localization and restores mitochondrial quality to rescue cell death.
therapy as promising strategies that merit exploration as therapies to treat human cardiomyopathy, resulting from this mutation. Expression of the human CryABR120G protein in cardiomyocytes impairs TFEB activation with marked impairment of autophagic flux. In contrast, IF and TFEB activation restore autophagic flux to remove protein aggregates, and simultaneously drive transcriptional upregulation of HSPB8, which binds to desmin and facilitates its physiologic localization to the intercalated discs and Z-lines (Figure 8H). This results in attenuation of cardiomyopathy.

Contemporary literature has fostered a paradigm shift in understanding the role of lysosomes as active cellular managers that drive catabolism via autophagy and other degradative pathways and couple substrate supply to intracellular metabolism. In contrast to the increased autophagic flux observed at early stages of the disease, we observe decreased autophagic flux accompanying advanced CryABR120G-induced cardiomyopathy. More important, although our experiments may have been underpowered to detect a difference between completely impaired versus reduced autophagic flux in CryABR120G mice at this advanced stage of cardiomyopathy, our results point to insufficient lysosome function in the setting of advanced protein aggregate pathologic features. Conceivably, the long-term increase in protein turnover upregulates amino acid availability, mimicking an “overfed” state, which drives an increase mTOR complex 1 activity. This results in phosphorylation and cytosolic sequestration of TFEB, the master regulator of the autophagy-lysosome machinery, with suppression of autophagic flux. Conversely, when these mice are subjected to nutrient deprivation by IF, this effect is overcome to inhibit mTOR complex 1 activity, resulting in TFEB activation. These effects are independent on an effect on

Figure 8. Continued
body weight, which is not affected by IF in mice on standard chow,26 (Figure S14C) and therefore points to tissue-specific signaling effects. Although prior studies have examined the notion that TFEB stimulates autophagic flux to remove R120G mutant of αB-crystallin,34 our data set is the first to comprehensively examine a clinically relevant paradigm for TFEB activation in vivo and explore relevant mechanisms. Intriguingly, TFEB transduction was sufficient to drive protein-aggregate removal via enhancing autophagic flux and restore normal desmin localization via HSPB8 induction, pointing to a broader role for the postlysosomal TFEB-mediated transcriptional program in facilitating protein quality control in cardiomyocytes. Furthermore, our data demonstrate that TFEB and HSPB8 play a critical mechanistic role in the IF-mediated rescue of cardiomyopathy and normalization of desmin localization. Whether the activation of TFEB prevents the development and progression of cardiomyopathy in this model remains to be explored.

Our studies suggest a model in which the relative abundance and competitive-binding affinities of CryABR120G and HSPB8 proteins to desmin dictate where desmin is localized to within the cardiomyocyte. Accordingly, in Myh6-CryABR120G hearts, despite a compensatory transcriptional upregulation of desmin protein levels, a large fraction of desmin is bound to the mutant αB-crystallin protein, thus localizing to aggregates rather than in association with the Z-discs and intercalated discs. In contrast, the fraction of desmin bound to HSPB8 dramatically increases with a concomitant decline in mutant αB-crystallin binding with IF and TFEB transduction, a scenario that favors physiologic desmin localization with attenuation of cardiomyopathic manifestations. Although we have not directly examined desmin degradation rates in vivo, our data demonstrating a lack of effect of IF on desmin transcripts, protein, and ubiquitination state support this model.

Prior studies have shown that CryABR120G protein aggregates into amyloid oligomers,41 a process that can be prevented by overexpression of the chaperones, HSPB8 (HSP22) and HSPB1 (HSP25),12; and transgenic expression of HSPB8 in cardiomyocytes prevents development of amyloid oligomers and cardiomyopathy.35 Our observations suggest that the desmin bound to the mutant crystallin protein is released on TFEB-induced protein-aggregate removal in the Myh6-CryABR120G hearts and is chaperoned by HSPB8 to its normal localization. Intriguingly, induction of HSPB8 promotes autophagic clearance of aggregate-prone proteins, such as mutant SOD1 (superoxide dismutase 1) and TDP43 (TAR DNA-binding protein 43) (implicated in amyotrophic lateral sclerosis) and polyglutamine repeat-bearing mutant androgen receptor (in spinal bulbar atrophy),42,43 and mutations in HSPB8 implicated in causing Charcot Marie tooth disease and distal hereditary motor neuropathy 2A impair autophagosome maturation in neuronal cell types.44 Our findings demonstrate that shRNA-mediated knockdown of HSPB8 had a modest effect on autophagic flux and autophagic clearance of αB-crystallin aggregates, in vivo; and HSPB8 expression was essential to restore desmin localization with TFEB expression in CryABR120G-expressing cardiomyocytes.

Normal localization of desmin in association with the Z-discs and intercalated discs plays a critical scaffolding role in maintaining mitochondrial polarization and function18,37 and sarcomere integrity.19 Mutations in the desmin tail that selectively impair its localization to the Z-disc,45 cause cardiomyopathy in humans,46 whereas experimental ablation of desmin in mice induces sarcomeric degeneration19 and a dilated cardiomyopathy with systolic dysfunction.20 Similarly, both missense mutations in desmin47 as well as a 7–amino acid deletion18 that impairs desmin assembly into intermediate filaments are sufficient to provoke an autosomal-dominant cardiomyopathy in humans.47,48 Reexpression of desmin via AAV9 transduction restored cardiac function and attenuated cardiomyopathy in desmin null mice.49 Indeed, the dominant-negative effect of CryABR120G protein may be to sequester desmin (and other sarcomeric proteins and chaperones) away from their physiologic intracellular localization sites.

Reduced myocardial cell death and fibrosis with IF and TFEB activation, in vivo, are consistent with the restoration of polarized mitochondria and attenuated cell death with TFEB expression in CryABR120G-expressing cardiomyocytes, in vitro studies. Indeed, mitochondrial abnormalities are observed in the desmin null myocardium as well as CryABR120G transgenic hearts, that result in mitochondrial permeabilization and cell death,5,33 which could be rescued by overexpression of an antiapoptotic protein, Bcl2.10,50 Our data suggest that IF or TFEB-induced normalization of desmin localization attenuates mitochondrial abnormalities as the proximate mechanism for attenuation of cardiomyopathy. Moreover, we have demonstrated that TFEB activation facilitates mitochondrial quality control via coordinated removal of damaged mitochondria and biogenesis of normal mitochondria under stress in cardiomyocytes, and this mechanism also needs to be formally evaluated in future studies.28

Our key finding, that IF and TFEB activation were sufficient to rescue established cardiomyopathy despite the markedly increased cell death9 and fibrosis7,15 seen at this advanced stage of pathogenesis, underscores the potential for restoring desmin to favorably remodel sarcomere in failing cardiomyocytes to treat desmin-related cardiomyopathies.2 Further, this paradigm may also be broadly relevant to cardiomyopathy and heart failure of diverse causes, in which abnormal desmin localization and protein aggregation are observed, such as in hearts from patients with hypertrophic cardiomyopathy with reduced VPS34 expression51 and from patients with dilated cardiomyopathy.41,52,53 More important,
these observations raise hopes for a therapeutic strategy targeting TFEB activation to slow or reverse disease pathogenesis, at a clinically relevant stage when most patients receive their initial diagnosis; and set the stage for experimental evaluation of therapies such as trehalose, a safe nonreducing disaccharide, or small molecules targeting mTOR that activate TFEB.

Acknowledgments

The authors thank Dr Wandy Beatty from Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO for performance of electron microscopy; and Joan Avery from the Center for Cardiovascular Research, Washington University School of Medicine, St. Louis, MO for technical assistance.

Author Contributions

Ma, Liu, Murphy, Foroughi, Kovacs, and Weinheimer performed experiments and analyzed the data; French, Benjamin, and Hill provided critical scientific reagents and scientific input; Kraja assisted with statistical analyses; Mani, Javaheri, and Diwan conceived the experiments; and Mani and Diwan wrote the article.

Sources of Funding

This study was supported by grants from the National Institutes of Health (HL107594) and the Department of Veterans Affairs (I01BX000448, I01BX001969, I01BX004235) to Diwan. Mani was supported by a Seed Grant from the St Louis VA Medical Center. Javaheri was supported by 5-T32-HL07081-40 and K08-HL138262 from the National Heart, Lung, and Blood Institute.

Disclosures

None.

References

1. Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetic basis of cardiomyopathy. J Am Coll Cardiol. 2016;68:2871–2886.
2. Goldfarb LG, Dalakas MC. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J Clin Invest. 2009;119:1806–1813.
3. Bova MP, Yaron O, Huang Q, Stevenson TJ, Peshock RM, Leopold JA, Barry WH, Loscalzo J, Javaheri S, Benjamin IJ. Human alpha B-crystallin mutation causes oedematous stress and protein aggregation cardiomyopathy in mice. Circ Res. 2007;103:1427–1439.
4. Maloyan A, Sanbe A, Osinska H, Westfall M, Robinson D, Imahashi K, Murphy E, Robbins J. Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. Circulation. 2005;112:3451–3461.
5. Maloyan A, Sayegh J, Osinska H, Chua BH, Robbins J. Manipulation of death pathways in desmin-related cardiomyopathy. Circ Res. 2010;106:1524–1532.
6. Liu J, Chen Q, Huang W, Horak KM, Zheng H, Mestril R, Wang X. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J. 2006;20:362–364.
7. sanbe A, Yamauchi J, Miyamoto Y, Fujiyara Y, Murabe M, Tanoue A. Interruption of CryAB-amyloid oligomer formation by HSP22. J Biol Chem. 2007;282:555–563.
8. Zhang H, Rajasekaran NS, Orosz A, Xiao J, Rechsteiner M, Benjamin IJ. Selective degradation of aggregate-prone CryAB mutants by HSP90 is mediated by ubiquitin-proteasome pathways. J Mol Cell Cardiol. 2010;49:918–930.
9. Li J, Horak KM, Su H, Sanbe A, Robbins J, Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest. 2011;121:3689–3700.
10. Bhuyan MS, Pattison JS, Osinska H, James J, Gulick J, McLendon PM, Hill JA, Sadoshima J, Robbins J. Enhanced autophagy ameliorates cardiac proteinopathy. J Clin Invest. 2013;123:5284–5297.
11. Pattison JS, Osinska H, Robbins J. Atg7 induces basal autophagy and rescues autophagic deficiency in CryAB120G cardiomyocytes. Circ Res. 2011;109:151–160.
12. Wang X, Osinska H, Dorn GW, Nieman M, Lorenz JN, Gerss AM, Wiggins S, Wawrousek EF. Mouse model of desmin-related cardiomyopathy. Circulation. 2001;103:2402–2407.
13. Milner DJ, Mavroidis M, Weisleder N, Capetanaki Y. Desmin cytoskeleton linked to muscle mitochondrial distribution and respiratory function. J Cell Biol. 2000;150:1283–1298.
14. Milner DJ, Weitzer G, Tran D, Bradley A, Capetanaki Y. Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol. 1996;134:1255–1270.
15. Milner DJ, Taffet GE, Wang X, Pham T, Tamura T, Hartley C, Gerss AM, Capetanaki Y. The absence of desmin leads to cardiomyocyte hypertrophy and cardiac dilation with compromised systolic function. J Mol Cell Cardiol. 1999;31:2063–2076.
16. Elliott JL, Der Perng M, Prescott AR, Janssen KA, Koenderink GH, Leopold JA. The specificity of the interaction between alphaB-crystallin and desmin filaments and its impact on filament aggregation and cell viability. Philos Trans R Soc Lond B Biol Sci. 2013;368:20120375.
17. Su H, Li J, Zhang H, Ma W, Wei N, Liu J, Wang X. COP9 signalosome controls autophagy to lysosomal biogenesis. Science. 2004;305:1007–1010.
18. Sayegh J, Osinska H, Mestrell R, Wang X. Impairment of ubiquitin-proteasome pathways in desminopathy mouse hearts. FASEB J. 2010;24:11092–11103.
19. Milner DJ, Bonduc V, Taffet GE, Wang X, Huynh T, Ferron M, Sabatini DM, Ballabio A. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31:1095–1108.
20. Godar RJ, Maloyan A, Siu D, Sadoshima J, Robbins J. Intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. Autophagy. 2015;11:1537–1560.
21. Brady JP, Garland DL, Green DE, Tamm ER, Giblin FJ, Wawrousek EF. AlphaB-crystallin in lens development and muscle integrity: a gene knockout approach. Invest Ophthalmol Vis Sci. 2001;42:2924–2934.
28. Ma X, Liu H, Murphy JT, Foyil SR, Godar RJ, Abuireqba H, Weinheimer CJ, Barger PM, Diwan A. Regulation of the transcription factor EB-PGC1α-alpha axis by beclin-1 controls mitochondrial quality and cardiomyocyte death under stress. *Mol Cell Biol*. 2015;35:956–976.

29. Ma X, Godar RJ, Liu H, Diwan A. Enhancing lysosome biogenesis attenuates BNIp3-induced cardiomyocyte death. *Autophagy*. 2012;8:297–309.

30. Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Tripoli DD, Czerniewski M, Ballabio A, Cirrito JR, Diwan A, Lee JM. Neuronal-targeted TFEB accelerates lysosomal degradation of APP, reducing Aβ generation and amyloid plaque pathogenesis. *J Neurosci*. 2015;35:12137–12151.

31. Konkalmatt PR, Beyers RJ, O’Connor DM, Xu Y, Seaman ME, French BA. Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling. *Circ Cardiovasc Imaging*. 2013;6:478–486.

32. Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O, Huynh T, Carissimo A, Palmer D, Kisch TJ, Wollenberg AC, Di Bernardo D, Chan L, Irazoqui JE, Ballabio A. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. *Nat Cell Biol*. 2013;15:647–658.

33. Maloyan A, Gulick J, Glabe CG, Kayed R, Robbins J. Exercise reverses premyeloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy. *Proc Natl Acad Sci USA*. 2007;104:5995–6000.

34. Pan B, Zhang H, Cui T, Wang X. TFEB activation protects against cardiac proteotoxicity via increasing autophagic flux. *J Mol Cell Cardiol*. 2017;113:51–62.

35. Sanbe A, Daicho T, Mizutani R, Endo T, Miyauchi N, Yamauchi J, Tanonaka K, Glabe CG, Vela E, Mate JL, Coll J, Fernandez-Figueras MT, Navas-Palacios JJ, Ariza A, Fuchs E. A dysfunctional desmin mutation in a patient with severe generalized myopathy. *Proc Natl Acad Sci USA*. 1998;95:11312–11317.

36. Heckmann MB, Bauer R, Jungmann A, Winter L, Rapti K, Strucksberg KH, Clemen CS, Li Z, Schroder R, Katus HA, Muller GJ. AAV9-mediated gene transfer of desmin ameliorates cardiomyopathy in desmin-deficient mice. *Gene Ther*. 2016;23:673–679.

37. Sjoberg G, Saavedra-Matiz CA, Rosen DR, Wijsman EM, Borg K, Horowitz SH, Sejersen T. A missense mutation in desmin tail domain linked to human dilated cardiomyopathy promotes cleavage of the head domain and abolishes its Z-disc localization. *FASEB J*. 2008;22:3318–3327.

38. Li D, Tapscoft T, Gonzalez O, Burch PE, Quinones MA, Zoghbi WA, Hill R, Bachinski LL, Mann DL, Roberts R. Desmin mutation responsible for idiopathic dilated cardiomyopathy. *Circulation*. 1999;100:461–464.

39. Sjoberg G, Saavedra-Matiz CA, Rosen DR, Wijsman EM, Borg K, Horowitz SH, Sejersen T. A missense mutation in desmin tail domain linked to human dilated cardiomyopathy promotes cleavage of the head domain and abolishes its Z-disc localization. *FASEB J*. 2008;22:3318–3327.

40. Sanbe A, Aoki T, Kita T, Takeuchi K, Nakajima T, Kato Y, Hasegawa T, Tanonaka K, Glabe CG, Kayed R, Robbins J. TFEB targets the desmin gene and regulates myo- fi laments and myocyte contractile dysfunction in dilated cardiomyopathy: an in vivo study in humans. *Heart*. 2000;84:659–667.
SUPPLEMENTAL MATERIAL
Data S1.

**Supplementary Methods:**

**Methods**

*Fasting studies in mice:* Mice were housed in groups of up to n = 5 mice/cage and fed standard chow (Lab Diet, 5053; providing 3.4 Kcal/g with 62.1% Kcal derived from carbohydrates, 13.2% from fats, and 24.6% from protein) on a 6:00 PM to 6:00 AM dark-light cycle. Intermittent fasting was performed with total food deprivation and ad libitum access to water while mice were housed on a cedar pine chip bedding from 12:00 PM to 12:00 PM of the following day to implement alternate periods of 24 h fasting and feeding, with change in bedding (AL indicates fed ad libitum and IF indicates that animals were provided access to food every other day). Non-fasted control mice were simultaneously provided fresh food with change in bedding. Terminal studies on mice were initiated between 8:00 to 10:00 AM after an overnight period of feeding (i.e., on a fed day). For fasting studies to determine the effects on HSPB8 transcript levels in the heart, mice were fasted for various durations beginning at 6:00 PM (the onset of the dark cycle during which mice typically feed).

*Echocardiography:* Echocardiography was performed using a Vevo 2100 Imaging System (VisualSonics, Toronto, Canada) equipped with a 30 MHz linear-array transducer according slight modifications of previously published methods. Briefly, mice were anesthetized using 0.1 g/kg IP Avertin (2,2,2-Tribromoethanol, Sigma-Aldrich, St. Louis, MO). Cardiac images were obtained by a handheld technique. Parasternal long- and short-axis images of the LV were used to guide acquisition of M-mode images at the papillary muscle level. Digitally recorded images were used to measure LV wall thickness (LV posterior wall, LVPW; interventricular septum, IVS) and chamber diameter (LVEDD) in end-diastole (d) and in end-systole (s). These measurements were used to calculate LV fractional shortening (LVFS=(100xLVEDD-LVESD)/LVEDD) and LV mass (LVM=[(LVPWd+IVSd+LVIDd)\(^3\)-LVIDd\(^3\)]x1.04).
Studies with neonatal rat cardiac myocytes (NRCMs): Primary cultures of neonatal rat cardiac myocytes were prepared as we have previously described. Hearts were harvested from one-day old neonatal rats, and the ventricles were subjected to trypsin (Invitrogen) digestion in a final concentration of 100 μg/ml in HBSS for 16 – 18 hours at 4°C after removal of the atria. Collagenase digestion (type II collagenase; 150 U/ml; Worthington) was conducted at 37 ° C for 45 min. The mixture of cells was plated for 2 h in flasks to exclude fibroblasts. The remaining non-adherent cardiomyocytes were seeded on collagen-coated four-well chamber slides (Laboratory Tek) at a density of 10⁵ cells per square cm. On the 2nd day the culture medium was changed to the Rat Cardiomyocyte Culture Medium (Cell applications INC, cat#R313-500) for at 3-5 days prior to desmin staining. NRCMs were treated with Bafilomycin A1 (BfA, Fisher scientific, cat#NC9686929): 200nM for 2 hours prior to harvest to assess autophagic flux, in vitro.

Isolation of soluble and insoluble fractions: The protocol described by Tannous et al was modified for this assay. Heart tissue was mechanically homogenized in 500-1000ul (depending on size of tissue) of homogenization buffer (0.3 M KCl, 0.1 M KH2PO4, 50 mM K2HPO4, 10 mM EDTA, 4 mM Na Orthovanadate, 100 mM NaF, Protease inhibitor, pH to 6.5). NRCMs were similarly homogenized with 20 strokes on ice with a Dounce homogenizer. Homogenized samples were passed through mesh basket on ice, followed by collection of the lysate run-through which was incubated on ice for 30 minutes. A known volume of the sample was transferred to another Eppendorf tube and 10% NP-40 was added to for a final concentration of 1% NP-40. Samples were then incubated on ice for 30 minutes, and spun at 13,000 rpm for 15 minutes, 4°C. Supernatant was collected as soluble fraction. The pellet was washed 3 times with cold PBS (following addition of 1ml PBS to each pellet, and spin down at 13,000 rpm for 10 minutes) followed by resuspension in 1% SDS, 10mM Tris buffer to generate the insoluble fraction.

Quantitation of desmin in aggregates by immuno-fluorescence: At least 10 images were obtained per heart from desmin stained whole heart sections of the left ventricle. 20X images were obtained with a 3x
zoom factor using a Zeiss Fluorescent microscope. After acquisition, images were converted into a JPG format using the Zeiss Zen software. Each image was analyzed using ImageJ software with a predetermined size threshold to exclude noise to obtain area of aggregates per section, depicted as a percentage of the total visualized area.

**Puromycin labeling to assess protein synthesis by the SunSET technique:** We utilized the SunSET technique to assess protein synthesis in the mouse heart. Mice were injected with puromycin (Enzo Life Sciences, Inc. cat#BML-GR312-0250) at a dose of 0.04 μmol/g body mass, i.p. 30 minutes prior to sacrifice. Cardiac tissue was homogenized in buffer I (50mM Tris HCl pH7.4, 2.5mM EDTA, 25mM NaCl, 0.2% NP 40, 10mM EGTA, 20mM NaFl, 25mM Na4O7P2, 2mM Na3VO4 with added Halt Protease and Phosphatase Inhibitor™, Thermo Scientific, cat# 78442) and subjected to SDS-PAGE electrophoresis. Anti-puromycin antibody (clone 12D10, cat# MABE343 from Millipore) was employed for immuno-detection of incorporated puromycin.
Table S1. List of primers for quantitative PCR analysis.

| Rat Genes | Forward (5’-3’) | Reverse (5’-3’) |
|-----------|-----------------|-----------------|
| HSP90aa1  | GCTTTTCAGAGCTGTTGAGATAC | AAAGGCTGAGTTAGCAACCTGG |
| HSPB1     | CGGCAACTCAGCAGCGGTGTCT | CATGTTTCATCTGCTTTCTTCGTG |
| HSPB8     | CCGGAAGAACTGATGGTAAAGAC | CCTCTGGAGAAAGTGAAGGCAAAATAC |
| CryAB     | CTTCTACCTCAGGGCCACCCTC | GCACCTCAATCAGTCTCCC |
| HSPBAP1   | GTACATTGTGGATCGGATCCCT | GGAAAGGTGTATCTCTCAAGGAGG |
| HSP70     | ACGAGGGTCCTCAAGGGCAAG | CTCTTTCTCAGCCAGCGTGTAG |
| RPL32     | CCTCTGGTGAGAAAGGCAAATAC | TCTGGGTTCGCCAGTTT |

| Mouse Genes | Forward (5’-3’) | Reverse (5’-3’) |
|-------------|-----------------|-----------------|
| Desmin      | GCGGCTTAAGAAACATCTCTGAGG | ATCTCGCAGGTGTAGGACTGGA |
| RPL32       | CCTCTGGTGAAAGCCCAAGATC | TCTGGGTTCGCCAGTTT |
Table S2. Evaluation of cardiac function by m-mode echocardiography in wild type ad lib fed mice and Myh6CryABR120G mice - either treated with ad lib feeding or intermittent fasting. Data shown is Mean ± SEM.

|                  | Wild type (n=5) | Myh6CryABR120G ad lib (n=7) | Myh6CryABR120G IF (n=7) |
|------------------|-----------------|-----------------------------|-------------------------|
| LVEDD (mm)       | 3.3 ± 0.1       | 4.2 ± 0.1*                  | 3.7 ± 0.1##             |
| LVESD (mm)       | 1.7 ± 0.1       | 3.2 ± 0.1*                  | 2.5 ± 0.2##             |
| FS (%)           | 49.6 ± 2.2      | 24.1 ± 1.5*                 | 32.6 ± 3.9##            |
| IVSd (mm)        | 0.70 ± 0.04     | 1.01 ± 0.06*                | 0.92 ± 0.03*            |
| PWTd (mm)        | 0.71 ± 0.03     | 0.85 ± 0.03*                | 0.81 ± 0.03*            |
| LVM (mg)         | 70 ± 5          | 152 ± 8*                    | 114 ± 3##               |
| r/h              | 2.3 ± 0.2       | 2.3 ± 0.1                   | 2.2 ± 0.1               |
| HR (beats/min)   | 603 ± 8         | 563 ± 18                    | 574 ± 20                |

* indicates p<0.05 by post-hoc testing after one way ANOVA vs. wild-type control.
# indicates p<0.05 by post-hoc testing after one way ANOVA for Myh6CryABR120G IF vs. ad-lib.

LVEDD = left ventricular end-diastolic dimension. LVESD = left ventricular end-systolic dimension. FS = fractional shortening. IVSd = diastolic thickness of the interventricular septum. PWTd = diastolic thickness of the posterior wall. LVM = left ventricular mass by echocardiography. r/h = radius to thickness ratio. HR = heart rate.
Table S3. Evaluation of cardiac function by M-mode echocardiography in wild type mice and Myh6CryABR120G mice treated with AAV9-GFP or AAV9-TFEB. All data are shown as Mean ± SEM.

|                        | Wild type AAV9-GFP (n=5) | Wild type AAV9-TFEB (n=5) | Myh6CryABR120G AAV9-GFP (n=8) | Myh6CryABR120G AAV9-TFEB (n=6) |
|------------------------|--------------------------|---------------------------|-------------------------------|-------------------------------|
| LVEDD (mm)             | 3.3 ± 0.1                | 3.2 ± 0.1                 | 4.2 ± 0.1*                   | 3.9 ± 0.1*                   |
| LVESD (mm)             | 1.8 ± 0.1                | 1.8 ± 0.1                 | 3.5 ± 0.1*                   | 2.8 ± 0.1**                  |
| FS (%)                 | 46.8 ± 1.3               | 45.8 ± 2.7                | 15.3 ± 1.4*                  | 28.1 ± 2.0**                 |
| IVSd (mm)              | 0.93 ± 0.04              | 0.97 ± 0.01               | 1.08 ± 0.02*                 | 1.00 ± 0.05                  |
| PWTd (mm)              | 0.8 ± 0.02               | 0.93 ± 0.04               | 0.96 ± 0.02*                 | 0.89 ± 0.03                  |
| LVM (mg)               | 97 ± 3                   | 106 ± 2                   | 172 ± 6*                     | 141 ± 6**                    |
| r/h                    | 1.9 ± 0.1                | 1.7 ± 0.1                 | 2.0 ± 0.1                    | 2.1 ± 0.1                    |
| HR (beats/min)         | 621 ± 15                 | 634 ± 13                  | 556 ± 25*                    | 532 ± 17*                    |

compared to respective AAV-GFP treated Wild type control group.

* indicates p<0.05 by post-hoc testing after one way ANOVA as compared to respective AAV-GFP treated Wild type control group.

# indicates p<0.05 by post-hoc testing after one way ANOVA AAV9-TFEB-treated vs. AAV9-GFP-treated Myh6CryABR120G TG mice.

LVEDD = left ventricular end-diastolic dimension. LVESD = left ventricular end-systolic dimension. FS = fractional shortening. IVSd = diastolic thickness of the interventricular septum. PWTd = diastolic thickness of the posterior wall. LVM = left ventricular mass by echocardiography. r/h = radius to thickness ratio. HR = heart rate.
Table S4. Evaluation of cardiac function by M-mode echocardiography in *Myh6CryaABR120G* mice treated with AAV9 control, AAV9 shTFEB, or AAV9shHspB8 and subjected to intermittent fasting (IF). The data are presented at T0 (prior to initiation of IF at 4 weeks post AAV injection), T3 (3 weeks after initiation of IF) and T6 (6 weeks after IF). All data are shown as Mean ± SEM.

| Myh6CryaABR120G | Myh6CryaABR120G | Myh6CryaABR120G |
|------------------|------------------|------------------|
|                  | AAV9-shControl   | AAV9-shTFEB      | AAV9-shHspB8      |
|                  | (n=5)            | (n=5)            | (n=4)            |
|                  | T0               | T3               | T6               |
|                  | T0               | T3               | T6               |
|                  | T0               | T3               | T6               |
| LVEDD (mm)       | 4.4 ± 0.2        | 4.4 ± 0.2        | 4.3 ± 0.2        |
|                  | 4.2 ± 0.1        | 4.6 ± 0.1        | 4.6 ± 0.1        |
|                  | 4.4 ± 0.3        | 4.7 ± 0.2        | 4.7 ± 0.1        |
| LVESD (mm)       | 3.3 ± 0.3        | 3.2 ± 0.3        | 2.9 ± 0.2        |
|                  | 3.2 ± 0.1        | 3.4 ± 0.11       | 3.5 ± 0.13$      |
|                  | 3.4 ± 0.3        | 3.8 ± 0.3*       | 3.8 ± 0.2*       |
| FS (%)           | 25.9 ± 3.3       | 28.1 ± 3.8       | 33.7 ± 2.0@      |
|                  | 25.2 ± 1.1       | 25.1 ± 1.1       | 24.4 ± 0.3*      |
|                  | 22.7 ± 2.9       | 19.0 ± 3.2*      | 19.6 ± 1.9*      |
| IVSd (mm)        | 0.8 ± 0.04       | 0.8 ± 0.02       | 0.8 ± 0.02       |
|                  | 0.8 ± 0.01       | 0.8 ± 0.02       | 0.8 ± 0.02       |
|                  | 0.8 ± 0.02       | 0.8 ± 0.02       | 0.8 ± 0.02       |
|                  | 0.8 ± 0.02       | 0.8 ± 0.02       | 0.8 ± 0.04       |
| PWTd (mm)        | 0.7 ± 0.02       | 0.7 ± 0.01       | 0.7 ± 0.02       |
|                  | 0.7 ± 0.01       | 0.7 ± 0.02       | 0.7 ± 0.01       |
|                  | 0.7 ± 0.01       | 0.7 ± 0.01       | 0.7 ± 0.03       |
| LVM (mg)         | 125 ± 15         | 120 ± 10         | 114 ± 6          |
|                  | 111 ± 6          | 127 ± 6          | 125 ± 6          |
|                  | 127 ± 14         | 144 ± 13         | 133 ± 10         |
| r/h              | 3.1 ± 0.1        | 3.0 ± 0.1        | 3.0 ± 0.1        |
|                  | 3.0 ± 0.1        | 3.1 ± 0.1        | 3.2 ± 0.1        |
|                  | 2.9 ± 0.2        | 3.1 ± 0.1        | 3.3 ± 0.2        |
| HR (beats/min)   | 556 ± 31         | 554 ± 13         | 557 ± 17         |
|                  | 515 ± 14         | 558 ± 14         | 581 ± 10         |
|                  | 526 ± 19         | 538 ± 17         | 555 ± 31         |

@ indicates p<0.05 by post-hoc testing after 2-way ANOVA for comparison of AAV9-shControl at the T6 timepoint as compared to baseline (T0).

* indicates p<0.05 by post-hoc testing after 2-way ANOVA for comparison of AAV9-shTFEB/shHspB8 groups vs. AAV9-shControl at the same time point.

$ indicates p = 0.06 by post-hoc testing after 2-way ANOVA for comparison of AAV9-shTFEB vs. AAV9-shControl at the same time point.

LVEDD = left ventricular end-diastolic dimension. LVESD = left ventricular end-systolic dimension. FS = fractional shortening. IVSd = diastolic thickness of the interventricular septum.
Figure S1. Autophagic flux assessment reveals preserved autophagic flux in skeletal muscle from Myh6-R120G αB-Crystallin TG mice and in the transgenic mouse hearts at a young age. A) Immuno-blot demonstrating LC3 and p62 expression in heart and skeletal muscle (gastrocnemius) tissue from 40 week old Myh6-R120G αB-Crystallin TG mice treated with CQ or diluent for autophagic flux assessment (representative of n=2 experiments). B, C) Representative immuno-blot (B) depicting LC3-II and p62 expression with quantitation (C) in young (8 week) Myh6-R120G αB-Crystallin TG mice treated with CQ or diluent for autophagic flux assessment. N=3/group. * indicates P<0.05 by t-test.
Figure S2. Expression of αB-Crystallin in Myh6-R120G αB-Crystallin TG mice and CryAB null mice demonstrates specificity for immuno-detection of αB-Crystallin. Immunoblot demonstrating expression of αB-Crystallin in hearts from Myh6-R120G αB-Crystallin TG mice, CryAB null mice and wild-type controls. Arrows point to various electrophoretic bands detected with the polyclonal αB-crystallin antibody employed herein.
Supplementary Figure S3: Intermittent fasting reduces aggregate pathology and myocardial cell death in Myh6-R120G αB-Crystallin TG mice. A) Quantitation of aggregates in the myocardium (as % area). B, C) Representative TUNEL stained images (with DAPI-stained nuclei, B) with quantitation of TUNEL+ nuclei (arrows in B, quantified in C) in hearts from Myh6-R120G αB-Crystallin TG mice subjected to intermittent fasting (IF) or ad-lib feeding for 6 weeks beginning at 40 weeks of age (see Fig. 2A for schematic) and WT controls (N=3-5/group). * indicates P<0.05 by t-test for A and by post-hoc test after one-way ANOVA for C.
Figure S4. Intermittent fasting and TFEB activation do not alter desmin transcription. A) Transcript abundance for desmin in hearts from Myh6-R120G αB-Crystallin TG mice subjected to intermittent fasting or ad-lib feeding, and littermate wild-type controls. N=4/group. * indicates P<0.05 by post-hoc test after one-way ANOVA. B) Transcript abundance for desmin in hearts from Myh6-R120G αB-Crystallin TG mice and littermate wild-type control mice transduced with AAV-TFEB or AAV-GFP. N=3-6/group. * indicates P<0.05 by post-hoc test after one-way ANOVA.
Figure S5: AAV-mediated TFEB transduction upregulates abundance of candidate autophagy-lysosome target proteins. A) Immunoblot depicting nuclear TFEB abundance in cardiac tissue from CryABR120G mice transduced with AAV-GFP or AAV-TFEB at 36 weeks of age, and sacrificed 10 weeks later. B-F) Representative immunoblot with quantification of protein abundance for LC3-II (C), LAMP1 (D), p62 (E) and LAMP2 (F) in cardiac tissue from wild-type mice transduced with AAV-GFP or AAV-TFEB at 36 weeks of age, and sacrificed 10 weeks later. * indicates P value by t-test. N=3/group.
Supplementary Figure S6: TFEB transduction does not alter transcript levels of the human CryAB R120G transgene and does not affect cardiac protein synthesis. A) Quantitative PCR analysis for detecting human CRYAB transgene expression with specific primer set (see Supplementary Table 1) in Myh6-R120G dB-Crystallin TG mice transduced with AAV-TFEB or AAV-GFP. N=4/group. B, C) Wild-type male C57bl6 mice (8 weeks old) were transduced with AAV-GFP or AAV-TFEB for 4 weeks and SunSET assay performed for assessing cardiac protein synthesis. Representative immuno-blot (B) with quantitation of puromycin incorporation (C) in cardiac extracts from a non-injected control mouse and AAV transduced mice. D) Representative immuno-blots for detecting mTOR activation state in mice treated as in B. P values were assessed by t-test in A and C.
Figure S7. TFEB transduction reduces aggregate pathology and myocardial cell death in Myh6-R120G αB-Crystallin TG mice. A) Quantitation of aggregates as % area of the myocardium in AAV-GFP and AAV-TFEB transduced mice at 46 weeks of age (see Figure 6A for images). N=3/group. * indicates P<0.05 by t-test. B, C) Representative TUNEL stained images (with DAPI-stained nuclei, B) with quantitation of TUNEL+ nuclei (pseudo-colored green, arrows in C) in hearts from Myh6-R120G αB-Crystallin TG mice and WT controls transduced with AAV9-TFEB or AAV9-GFP for 10 weeks beginning at 36 weeks of age (see Fig. 5A for schematic) and WT controls (N=3-4/group). * indicates P<0.05 by post-hoc test after one-way ANOVA.
Figure S8. TFEB induces HSPB8 expression. Transcript abundance of various heat shock protein family members in NRCMs adenovirally transduced with HA-tagged TFEB or Ad-LacZ (MOI=10 each) for 24 hours. N=3-4/group. * indicates P<0.05 by t-test.
Figure S9. Fasting increases HSPB8 transcript and protein levels in the myocardium. A) HSPB8 transcript levels in cardiac tissue from C57Bl6 wild-type mice fasted for various durations as shown. N=4/group. * indicates P<0.05 by post-hoc analysis after one way ANOVA.

B, C) Representative immunoblot (B) and quantitation of HSPB8 protein levels (C) in the myocardium from fed wild-type mice, mice fasted for 24 hours, and mice fasted for 24 hours followed by re-feeding for 24 hours. N=3/group. * indicates P<0.05.

D, E) Representative immunoblot (D) and quantitation of HSPB8 protein levels (E) in the myocardium from Myh6-R120G dB-Crystallin TG mice subjected to intermittent fasting (IF) or ad-lib feeding for 6 weeks beginning at 40 weeks of age (see Fig. 2A for schematic) and WT controls (N=4/group). * indicates P<0.05 by post-hoc test after one-way ANOVA.
Figure S10. R120G mutant CRYAB protein interacts more strongly with desmin than the wild-type CRYAB protein, in vivo. A) Male C57Bl/6 mice at 8 weeks of age were transduced with AAV9 particles with cardiac troponin T promoter driven expression of FLAG-tagged human CRYAB protein or its R120G mutant for 4 weeks. Representative immuno-blot demonstrating expression of FLAG-tagged CRYAB proteins is shown in A. Mice not treated with AAV9 particles are shown as control; 'ns' indicates non-specific band. B) Quantitation of FLAG-tagged CRYAB protein and its R120G mutant in cardiac extracts from mice treated as in A. N=3/group. NS indicates not-significant for P value by t-test. C) Immuno-precipitation was performed with anti-FLAG antibody (or IgG control) in cardiac extracts from mice treated as in A and immuno-blot performed for desmin and CRYAB. Representative immuno-blot is shown. D) Quantitation of desmin expression in after immuno-precipitation with anti-FLAG antibody as shown in C. N=3/group. * indicates P<0.05 by t-test.
**Figure S11. Intermittent fasting does not alter desmin ubiquitination.**

Immunoblot demonstrating poly-ubiquitinated desmin in Myh6-CryABR120G TG mice subjected to intermittent fasting (IF) or ad-lib (AL) feeding and littermate control hearts (depicted as “-”). One mg of total protein from cardiac extracts was subjected to immunoprecipitation with anti-desmin antibody or control IgG, followed by immuno-blotting for ubiquitin. The immunoblot for desmin is reproduced from the blot shown in Figure 6F. At the exposure shown to demonstrate desmin in TG samples, a desmin signal was not evident in WT hearts in the input lane (with 20 micrograms/sample; and was seen with longer exposure times (data not shown)).
Figure S12. TFEB promotes clearance of αB-crystallin via induction of autophagic flux, independent of HSPB8 in NRCMs. A) Representative immunoblot demonstrating assessment of autophagic flux and HSPB8 expression in NRCMs adenovirally transduced with R120G mutant of αB-crystallin (MOI=10; for 48 hours) without or with HATagged TFEB (MOI=10; for 24 hours) in the presence of adenoviral particles expressing shRNA targeting rat HSPB8 (shHSPB8; MOI=100 for 72 hours) and treated with bafilomycin A1 (BfA; 200nM or diluent for 2 hours) to inhibit lysosomal acidification. Adenoviral particles coding for LacZ or shLacZ were added as controls simultaneously with Ad-TFEB or Ad-αB-crystallin overexpression and sh-HSPB8, respectively, to equalize the number of viral particles. B-D) Quantitation of HSPB8 (B), LC3-II (C) and p62 (D) expression in NRCMs treated as in A. N=3/group. * indicates P<0.05 by t-test within BfA and diluent treated groups; and # indicates P<0.05 by post-hoc test after one-way ANOVA for comparisons within the diluent treated group only. E) Quantitation of αB-crystallin expression in the non-BfA treated samples from A. * indicates P<0.05 by one-way ANOVA.
Figure S13. TFEB promotes removal of αB-Crystallin aggregates in NRCMs. Immunoblot demonstrating αB-Crystallin expression in soluble and insoluble fractions from NRCMs adenovirally transduced with R120G mutant of αB-Crystallin (MOI=10; for 48 hours) without or with HA-tagged TFEB (MOI=10; for 24 hours). Adenoviral particles coding for LacZ were added as controls simultaneously to equalize the number of viral particles.
Figure S14. Knockdown of TFEB and HSPB8 prevents intermittent fasting-mediated attenuation of proteotoxic cardiomyopathy. A) Schematic depicting experimental intervention with AAV9-mediated shRNA transduction (directed to either TFEB or HSPB8 vs. control shRNA) in 36 week old Myh6-CryABR120G TG mice. Four weeks after AAV injection, baseline echocardiograms were obtained followed by 6 weeks of intermittent fasting (termed T=0 time point). Serial echocardiograms were then obtained at 3 weeks and 6 weeks (termed T=3 and T=6 time points, respectively), followed by sacrifice and post mortem biochemical, microscopic and immuno-histochemical analysis. B) Immunoblot depicting levels of nuclear TFEB after transduction with shTFEB vs. shCon. C) Left ventricular end-diastolic diameter assessed as fold-change compared to baseline (T=0 weeks) data-point in the control group, in mice treated as in A. N=4-5/group. * indicates P<0.05 by post-hoc test after two-way ANOVA. D) Body weight over the duration of the study in mice treated as in A. N=4-5/group. * indicates P<0.05 by post-hoc test after two-way ANOVA. D) Representative immuno-blot demonstrating expression of LC3 and p62 in mice modeled as in A and injected with chloroquine (40 mg/kg) 4 hours prior to sacrifice to assess autophagic flux. Representative of n=2 experiments.
Figure S15. Knockdown of TFEB and HSPB8 prevents intermittent fasting-mediated removal of aggregates with persistent desmin localization to aggregates. A) Quantitation of aggregates as % area of the myocardium in Myh6-CryABR120G TG mice transduced with AAV9-shControl, AAV9-shTFEB or AAV9-shHSPB8 for 4 weeks at age of 36 weeks and subjected to intermittent fasting, assessed at 46 weeks of age. See Figure 8G for representative images. N=3/group. P value is by post-hoc test after one-way ANOVA. B, C) Representative immuno-blot (B) with quantitation of αB-crystallin in insoluble (C) myocardial fractions from Myh6-CryABR120G TG mice at 46 weeks of age injected with AAV9 particles coding for shRNAs targeting TFEB or HSPB8, or control for 4 weeks and then subjected to intermittent fasting for 6 weeks. N=3/group. P value is by post-hoc test after one-way ANOVA.
1) **Figure 1B:**

Exact Permutation Test (complete enumeration)

data:  WT dil and WT CQ  
p-value = 0.002165  
alternative hypothesis: true mean s10 - mean s20 is 0  
sample estimates:  
mean WT dil - mean WT cq  
-0.5683489

data:  CryAB dil and CryAB CQ  
p-value = 0.9524  
alternative hypothesis: true mean s11 - mean s21 is 0  
sample estimates:  
mean CryAB dil - mean CryAB CQ  
0.1116057
2) Figure 1C:

```
data:  WT dil and WT CQ
p-value = 0.002165
alternative hypothesis: true mean s10 - mean s20 is 0
sample estimates:
mean WT dil - mean WT CQ
-0.5683489

data:  CryAB dil and CryAB CQ
p-value = 0.9524
alternative hypothesis: true mean s11 - mean s21 is 0
sample estimates:
mean CryAB dil - mean CryAB CQ
0.1116057
```
3) **Figure 1D**

Exact Permutation Test (complete enumeration)

data:  WT dil and WT CQ  
p-value = 0.002165  
alternative hypothesis: true mean s10 - mean s20 is 0  
sample estimates:  
mean WT dil - mean WT CQ  
-0.5683489

data:  CryAB dil and CryAB CQ  
p-value = 0.9524  
alternative hypothesis: true mean s11 - mean s21 is 0  
sample estimates:  
mean CryAB dil - mean CryAB CQ  
0.1116057
4) **Figure. 2D**

![Bar graph showing data analysis results](chart.png)

**Exact Permutation Test (complete enumeration)**

Data: WT and CryAb AL

- p-value = 0.02857
- Alternative hypothesis: true mean s10 - mean s11 is 0
- Sample estimates:
  - mean s10 - mean s11: 0.5142135

Data: Cyto: CryAB AL and CryAB IF

- p-value = 0.08571
- Alternative hypothesis: true mean s11 - mean s12 is 0
- Sample estimates:
  - mean s11 - mean s12: -0.2665246

Data: Nuc: CryAB AL and CryAB IF

- p-value = 0.02857
- Alternative hypothesis: true mean s21 - mean s22 is 0
- Sample estimates:
  - mean s21 - mean s22: -0.5184553
5) Figure 2F

Exact Permutation Test (complete enumeration)

data: LC3-II CryAB R120G IF dil vs. CRYAB R120G IF CQ
p-value = 0.0079
alternative hypothesis: true mean s12 - mean s13 is
sample estimate
mean s12 - mean s1
-0.391546

data: p62 CryAB R120G IF dil vs. CRYAB R120G IF CQ
p-value = 0.0079
alternative hypothesis: true mean s22 - mean s23 is
sample estimate
mean s22 - mean s2
-0.3453506
Exact Permutation Test (complete enumeration)

data:  LAMP1: WT and CRYAB AL  
\[ p\text{-value} = 0.02857 \]
alternative hypothesis: true mean s10 - mean s11 is 0
sample estimates:
mean s10 - mean s11
  0.3220731

data:  LAMP1: CRYAB AL and CRYAB IF  
\[ p\text{-value} = 0.02857 \]
alternative hypothesis: true mean s11 - mean s12 is 0
sample estimates:
mean s11 - mean s12
  -0.2118281

data:  LAMP2: WT and CRYAB AL  
\[ p\text{-value} = 0.02857 \]
alternative hypothesis: true mean s20 - mean s21 is 0
sample estimates:
mean s20 - mean s21
  0.3928372

data:  LAMP2: CRYAB AL and CRYAB IF  
\[ p\text{-value} = 0.02857 \]
alternative hypothesis: true mean s21 - mean s22 is 0
sample estimates:
mean s21 - mean s22
  -0.2607011
7) **Figure 2J**

![Figure 2J](image)

**Exact Permutation Test (complete enumeration)**

- **pMTOR/mTOR WT vs. CRYAB AL**
  - p-value = 0.02857
  - alternative hypothesis: true mean s10 - mean s11 is 0
  - sample estimates:
    - mean s10 - mean s11 = -1.810188

- **pMTOR/mTOR CRYAB AL vs. CRYAB IF**
  - p-value = 0.02857
  - alternative hypothesis: true mean s11 - mean s12 is 0
  - sample estimates:
    - mean s11 - mean s12 = 0.9711987

- **p-S6K/S6K WT vs. CRYAB AL**
  - p-value = 0.02857
  - alternative hypothesis: true mean s20 - mean s21 is 0
  - sample estimates:
    - mean s20 - mean s21 = -1.134393

- **S6K/S6K CRYAB AL vs. CRYAB IF**
  - p-value = 0.02857
  - alternative hypothesis: true mean s21 - mean s22 is 0
  - sample estimates:
    - mean s21 - mean s22 = 0.7850461

- **p-4EBP1/4EBP1 WT vs. CRYAB AL**
  - p-value = 0.02857
  - alternative hypothesis: true mean s30 - mean s31 is 0
sample estimates:
mean s30 - mean s31
-1.134386

data:  p-4EBP1/4EBP1 CRYAB AL vs. CRYAB IF
p-value = 0.02857
alternative hypothesis: true mean s31 - mean s32 is 0
sample estimates:
mean s31 - mean s32
0.7850461
Exact Permutation Test (complete enumeration)

data: CRYAB AL vs. IF
p-value = 0.02857
alternative hypothesis: true mean s1 - mean s2 is 0
sample estimates:
mean s1 - mean s2
-0.2432008
9) **Figure 3C**

![Bar chart](image)

**Exact Permutation Test (complete enumeration)**

data: CRYAB AL vs. IF  
p-value = 0.02857  
alternative hypothesis: true mean s1 - mean s2 is 0  
sample estimates:  
mean s1 - mean s2  
-0.3708712
10) Figure 4B

- **data: WTAL vs. CRYAB AL**
  - p-value = 0.001263
  - alternative hypothesis: true mean s2 - mean s3 is 0
  - sample estimates:
    - mean s2 - mean s3
      - 0.8959714

- **data: CRYAB IF and CRYAB AL**
  - p-value = 0.006993
  - alternative hypothesis: true mean s1 - mean s3 is 0
  - sample estimates:
    - mean s1 - mean s3
      - 0.4657143

- **data: CRYAB IF and WT AL**
  - p-value = 0.005051
  - alternative hypothesis: true mean s1 - mean s2 is 0
  - sample estimates:
    - mean s1 - mean s2
      - 0.4302571
11) Figure 4C

Exact Permutation Test (complete enumeration)
data: CRYAB AL vs. IF

p-value = 0.001263
alternative hypothesis: true mean s2 - mean s3 is 0
sample estimates:
mean s2 - mean s3
25.54954

Exact Permutation Test (complete enumeration)
data: WTAL vs. CRYAB AL
p-value = 0.08159
alternative hypothesis: true mean s2 - mean s3 is 0
sample estimates:
mean s2 - mean s3
25.54954

Exact Permutation Test (complete enumeration)
data: CRYAB IF and CRYAB AL
p-value = 0.08159
alternative hypothesis: true mean s1 - mean s3 is 0
sample estimates:
mean s1 - mean s3
8.524286

Exact Permutation Test (complete enumeration)
data: CRYAB IF and WT AL
p-value = 0.01136
alternative hypothesis: true mean s1 - mean s2 is 0
sample estimates:
mean s1 - mean s2
-17.02526
12) Figure 4D

Exact Permutation Test (complete enumeration)

data: CRYAB AL vs. IF  
p-value = 0.001263  
alternative hypothesis: true mean s2 - mean s3 is 0  
sample estimates:  
mean s2 - mean s3  
-82.17463
Exact Permutation Test (complete enumeration)

data:  CRYAB AL vs. IF
p-value = 0.0001998
alternative hypothesis: true mean s2 - mean s3 is  0
sample estimates:
mean s2 - mean s3
  -4.391861

data:  CRYAB IF and CRYAB AL
p-value = 0.01132
alternative hypothesis: true mean s1 - mean s3 is  0
sample estimates:
mean s1 - mean s3
  -1.983246

data:  CRYAB IF and WT AL
p-value = 4.114e-05
alternative hypothesis: true mean s1 - mean s2 is  0
sample estimates:
mean s1 - mean s2
  2.408615
14) Figure 5C

Data: TFEB WT AAV GFP and WT AAV TFEB
p-value = 0.004329
Alternative hypothesis: true mean s2 - mean s3 is 0
Sample estimates:
mean s2 - mean s3
0.9304463

Data: TFEB CRYAB AAV GFP and CRYAB AAV TFEB
p-value = 0.0005828
Alternative hypothesis: true mean s1 - mean s4 is 0
Sample estimates:
mean s1 - mean s4
0.995846
data: Crystallin WT AAV GFP and WT AAV TFEB
p-value = 0.002165
alternative hypothesis: true mean s2 - mean s3 is 0
sample estimates:
mean s2 - mean s3
  0.9835765

data: Crystallin WT AAV GFP and CRYAB AAV TFEB
p-value = 0.002165
alternative hypothesis: true mean s2 - mean s4 is 0
sample estimates:
mean s2 - mean s4
 -17.61125

data: Crystallin CRYAB AAV GFP and CRYAB AAV TFEB
p-value = 0.0005828
alternative hypothesis: true mean s1 - mean s4 is sample estimates:
mean s1 - mean s4
 -6.151504
15) **Figure 5E**

Exact Permutation Test (complete enumeration)

data:  WT + AAV GFP VS. CRYAB R120 + AAV GFP  
p-value = 0.000777  
alternative hypothesis: true mean s3 - mean s4 is 0  
sample estimates:  
mean s3 - mean s4  
-0.8395

data:  CRYABR120G + AAV GFP VS. CRYAB R120 + AAV TFEB  
p-value = 0.1593  
alternative hypothesis: true mean s1 - mean s4 is 0  
sample estimates:  
mean s1 - mean s4  
-0.2455
16) Figure 5F

Exact Permutation Test (complete enumeration)

data: CRYAB R120G AAV GFP VS. CRYAB R120G AAV TFEB
p-value = 0.001554
alternative hypothesis: true mean s1 - mean s4 is 0
sample estimates:
mean s1 - mean s4
12.76925

data: CRYAB R120G AAV TFEB and WT AAV9 GFP
p-value = 0.007937
alternative hypothesis: true mean s1 - mean s3 is 0
sample estimates:
mean s1 - mean s3
-18.662

data: CRYAB R120G AAV GFP and WT AAV9 GFP
p-value = 0.000777
alternative hypothesis: true mean s3 - mean s4 is 0
sample estimates:
mean s3 - mean s4
31.43125
Figure 5G

Exact Permutation Test (complete enumeration)

data: CRYAB R120G AAV GFP vs. CRYAB R120G AAV TFEB
p-value = 0.003108
alternative hypothesis: true mean s1 - mean s4 is 0
sample estimates:
mean s1 - mean s4
-31.3035

data: CRYAB R120G AAV TFEB and WT AAV9 GFP
p-value = 0.007937
alternative hypothesis: true mean s1 - mean s3 is 0
sample estimates:
mean s1 - mean s3
44.326

data: CRYAB R120G AAV GFP and WT AAV9 GFP
p-value = 0.000777
alternative hypothesis: true mean s3 - mean s4 is 0
sample estimates:
mean s3 - mean s4
-75.6295
Exact Permutation Test (complete enumeration)

data: CRYAB R120G AAV GFP vs. CRYAB R120G AAV TFEB
p-value = 0.003108
alternative hypothesis: true mean s1 - mean s4 is 0
sample estimates:
mean s1 - mean s4
-31.3035

data: CRYAB R120G AAV TFEB and WT AAV9 GFP
p-value = 0.007937
alternative hypothesis: true mean s1 - mean s3 is 0
sample estimates:
mean s1 - mean s3
44.326

data: CRYAB R120G AAV GFP and WT AAV9 GFP
p-value = 0.000777
alternative hypothesis: true mean s3 - mean s4 is 0
sample estimates:
mean s3 - mean s4
-75.6295
19) Figure 6C

Exact Permutation Test (complete enumeration)

data:  HSPB8/ACTIN WT AAV GFP vs. WT AAV TFEB
p-value = 0.0303
alternative hypothesis: true mean s2 - mean s3 is  0
sample estimates:
mean s2 - mean s3
  1.144588

data:  HSPB8/ACTIN WT AAV GFP vs. CRYAB R120G AAV GFP
p-value = 0.002165
alternative hypothesis: true mean s3 - mean s4 is  0
sample estimates:
mean s3 - mean s4
  -3.923404

data:  HSPB8/ACTIN CRYAB R120G AAV GFP vs. CRYAB R120G AAV TFEB
p-value = 0.01166
alternative hypothesis: true mean s1 - mean s4 is  0
sample estimates:
mean s1 - mean s4
  2.077214

data:  HSPB8/ACTIN WT AAV GFP vs. CRYAB R120G AAV TFEB
p-value = 0.001263
alternative hypothesis: true mean s1 - mean s3 is  0
sample estimates:
mean s1 - mean s3
6.000618
20) Figure 6D

Exact Permutation Test (complete enumeration)

data: HSPB1/ACTIN WT AAV GFP vs. CRYABR120G AAV GFP
p-value = 0.01786
alternative hypothesis: true mean s1 - mean s3 is 0
sample estimates:
mean s1 - mean s3
3.960078

data: HSPB1/ACTIN WT AAV TFEB vs. CRYABR120G AAV TFEB
p-value = 0.007937
alternative hypothesis: true mean s1 - mean s2 is 0
sample estimates:
mean s1 - mean s2
3.93306
Exact Permutation Test (complete enumeration)

data: DESMIN/ACTIN WT AAV GFP vs. CRYAB R120G AAVGFP
p-value = 0.002165
alternative hypothesis: true mean s3 - mean s4 is 0
sample estimates:
mean s3 - mean s4
-1.840548

data: DESMIN/ACTIN WT AAV TFEB vs. CRYAB R120G AAVTFEB
p-value = 0.001166
alternative hypothesis: true mean s1 - mean s2 is 0
sample estimates:
mean s1 - mean s2
1.977417
Figure 7D

**Exact Permutation Test (complete enumeration)**

data: JC-1 DEPOLARIZATION: Ad LacZ + Ad CRYAB R120G vs. Ad TFEB + Ad CRYAB R120G
p-value = 0.0005828
alternative hypothesis: true mean s13 - mean s14 is 0
sample estimates:
mean s13 - mean s14
1.747366

data: JC-1 depol.: Ad TFEB + Ad CRYAB R120G vs. Ad TFEB + Ad CRYAB R120G + Ad sh-HSPB8
p-value = 0.0005828
alternative hypothesis: true mean s14 - mean s15 is 0
sample estimates:
mean s14 - mean s15
-1.709391

data: JC-1 DEPOLARIZATION: Ad LacZ vs. Ad LacZ + Ad CRYAB R120G
p-value = 0.0005828
alternative hypothesis: true mean s10 - mean s13 is 0
sample estimates:
mean s10 - mean s13
-2.200875

data: JC-1 DEPOLARIZATION: Ad LacZ vs. Ad TFEB + Ad CRYAB R120G
p-value = 0.0005828
alternative hypothesis: true mean s10 - mean s14 is 0
sample estimates:
mean s10 - mean s14
-0.4535086

data: JC-1 DEPOLARIZATION: Ad LacZ vs. Ad LacZ + Ad shHSPB8
p-value = 0.0005828
alternative hypothesis: true mean s10 - mean s12 is 0
sample estimates:
mean s10 - mean s12
-0.4109876

data: JC-1 DEPOLARIZATION: Ad LacZ vs. Ad TFEB+ AD CRYABR120G + Ad shHSPB8
p-value = 0.0005828
alternative hypothesis: true mean s10 - mean s15 is 0
sample estimates:
mean s10 - mean s15
-2.1629
Mitochondrial DNA quantitation

Exact Permutation Test (complete enumeration)

data:  MitoDNA:  Ad LacZ + Ad CRYAB R120G  vs.  Ad TFEB + Ad CRYAB R120G
p-value = 0.02857
alternative hypothesis: true mean s13 - mean s14 is  0
sample estimates:
mean s13 - mean s14
0.4075

data:  MitoDNA:  Ad TFEB + Ad CRYAB R120G  vs.  Ad TFEB + Ad CRYAB R120G + Ad sh-HSPB8
p-value = 0.02857
alternative hypothesis: true mean s14 - mean s15 is  0
sample estimates:
mean s14 - mean s15
-0.44

data:  MitoDNA:  Ad LacZ vs.  Ad LacZ + Ad CRYAB R120G
p-value = 0.02857
alternative hypothesis: true mean s10 - mean s13 is  0
sample estimates:
mean s10 - mean s13
data: MitoDNA: Ad LacZ vs. Ad TFEB + Ad CRYAB R120G
p-value = 0.02857
alternative hypothesis: true mean s10 - mean s14 is 0
sample estimates:
mean s10 - mean s14
-0.29

data: MitoDNA: Ad LacZ vs. Ad LacZ + Ad shHSPB8
p-value = 0.02857
alternative hypothesis: true mean s10 - mean s12 is 0
sample estimates:
mean s10 - mean s12
-0.3775

data: MitoDNA: Ad LacZ vs. Ad TFEB + AD CRYABR120G + Ad shHSPB8
p-value = 0.02857
alternative hypothesis: true mean s10 - mean s15 is 0
sample estimates:
mean s10 - mean s15
-0.73
Exact Permutation Test (complete enumeration)

data:  Ad LacZ + Ad CRYAB R120G  vs. Ad TFEB + Ad CRYAB R120G
p-value = 0.0001554
alternative hypothesis: true mean s4 - mean s5 is  0
sample estimates:
mean s4 - mean s5
   6.829617

data:  Ad TFEB + Ad CRYAB R120G  vs. Ad TFEB + Ad CRYAB R120G + Ad sh-HSPB8
p-value = 0.0001554
alternative hypothesis: true mean s5 - mean s6 is  0
sample estimates:
mean s5 - mean s6
  -7.874323

data: Ad LacZ vs. Ad LacZ + Ad CRYAB R120G
p-value = 0.0001554
alternative hypothesis: true mean s1 - mean s4 is  0
sample estimates:
mean s1 - mean s4
   -9.49469

data: Ad LacZ vs. Ad TFEB + Ad CRYAB R120G
p-value = 0.006838
alternative hypothesis: true mean s1 - mean s5 is  0
sample estimates:
mean s1 - mean s5
-2.665073

data: Ad LacZ vs. Ad LacZ + Ad shHSPB8
p-value = 0.02455
alternative hypothesis: true mean s1 - mean s3 is 0
sample estimates:
mean s1 - mean s3
-1.78758

data: Ad LacZ vs. Ad TFEB+ AD CRYABR120G + Ad shHSPB8
p-value = 0.0001554
alternative hypothesis: true mean s1 - mean s6 is 0
sample estimates:
mean s1 - mean s6
-10.5394
Exact Permutation Test (complete enumeration)

- **Data:** AAV sh control and sh TFEB
  - **P-value:** 0.02857
  - **Alternative hypothesis:** true mean s10 - mean s11 is 0
  - **Sample estimates:**
    - mean s10 - mean s11
      - 0.7235474

- **Data:** sh TFEB and sh HSPB8
  - **P-value:** 0.02857
  - **Alternative hypothesis:** true mean s11 - mean s12 is 0
  - **Sample estimates:**
    - mean s11 - mean s12
      - -0.4478951
data: sh Control and sh TFEB
p-value = 0.02857
alternative hypothesis: true mean s10 - mean s11 is 0
sample estimates:
mean s10 - mean s11
0.2165965

data: sh TFEB and sh HSPB8
p-value = 0.02857
alternative hypothesis: true mean s11 - mean s12 is 0
sample estimates:
mean s11 - mean s12
0.5273424

data: sh Control and sh HSPB8
p-value = 0.02857
alternative hypothesis: true mean s10 - mean s12 is 0
sample estimates:
mean s10 - mean s12
0.743939
27) Figure 8D

Exact Permutation Test (complete enumeration)

data: sh Control baseline and sh Control 6wk
p-value = 0.03968
alternative hypothesis: true mean s10 - mean s30 is 0
sample estimates:
mean s10 - mean s30
-7.7552

data: sh control baseline and shHSPB8 baseline
p-value = 0.07937
alternative hypothesis: true mean s20 - mean s21 is 0
sample estimates:
mean s20 - mean s21
9.0979

data: sh Control 6wk and sh TFEB 6wk
p-value = 0.007937
alternative hypothesis: true mean s30 - mean s31 is 0
sample estimates:
mean s30 - mean s31
14.0881

data: sh Control 6wk and sh HSPB8 6wk
p-value = 0.007937
alternative hypothesis: true mean s30 - mean s32 is 0
sample estimates:
mean s30 - mean s32
9.2062
Supplemental References:

1. Godar RJ, Ma X, Liu H, Murphy JT, Weinheimer CJ, Kovacs A, Crosby SD, Saftig P and Diwan A. Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. *Autophagy*. 2015;11:1537-60.

2. Syed F, Diwan A and Hahn HS. Murine echocardiography: a practical approach for phenotyping genetically manipulated and surgically modeled mice. *JAmSocEchocardiogr*. 2005;18:982-990.

3. Cilvik SN, Wang JI, Lavine KJ, Uchida K, Castro A, Gierasch CM, Weinheimer CJ, House SL, Kovacs A, Nichols CG and Ornitz DM. Fibroblast growth factor receptor 1 signaling in adult cardiomyocytes increases contractility and results in a hypertrophic cardiomyopathy. *PloS one*. 2013;8:e82979.

4. Ma X, Liu H, Foyil SR, Godar RJ, Weinheimer CJ, Hill JA and Diwan A. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. *Circulation*. 2012;125:3170-3181.

5. Tannous P, Zhu H, Johnstone JL, Shelton JM, Rajasekaran NS, Benjamin IJ, Nguyen L, Gerard RD, Levine B, Rothermel BA and Hill JA. Autophagy is an adaptive response in desmin-related cardiomyopathy. *ProcNatlAcadSciUSA*. 2008;105:9745-9750.

6. Ravi V, Jain A, Ahamed F, Fathma N, Desingu PA and Sundaresan NR. Systematic evaluation of the adaptability of the non-radioactive SUnSET assay to measure cardiac protein synthesis. *Sci Rep*. 2018;8:4587.